CLINICAL PROTOCOL  
A Phase 2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of 
Ataluren (PTC124®) in Patients Aged ≥2 to <[ADDRESS_386683]  
South Plainfield, NJ [ZIP_CODE] [LOCATION_003]  
Notice  of  Proprietary  Information:  This  document  contains  confidential  information   belonging   to PTC 
Therapeutics, Inc. Except as may otherwise be permitted in writing, by [CONTACT_99458], 
you agree that this information should not be disclosed to others (except where required by [CONTACT_1289]) and should not be used for unauthorized purposes. In the event of an actual or suspected breach of this obligation, 
PTC Therapeutics, Inc. should be notified  promptly.  [STUDY_ID_REMOVED]
Protocol Number PTC1240- GD-030- DMD [ADDRESS_386684]  Code  PTC124- GD 
Therapeutic Area  Genetic Disorders – Duchenne Muscular Dystrophy 
PTC Therapeutics  Substance  Identifier  Ataluren  (PTC124) 
IND Number  68,431 
Included in clinical  trials.gov Database Pending 
Protocol Number  PTC124- GD-030- DMD  
Protocol Version  Version 2.0 
Protocol Phase Phase 2 
Protocol Title A Phase 2 Stu dy of the Safety, Pharmacokinetics, 
and Pharmacodynamics of Ataluren (PTC124®) 
in Patients Aged ≥2 to <[ADDRESS_386685] South Plainfield, NJ [ZIP_CODE] [LOCATION_003] Telephone (office):  
Facsimile:  
E-mail:  
PTC Biostatistician   
PTC Therapeutics, Inc. [ADDRESS_386686] South Plainfield, NJ [ZIP_CODE] [LOCATION_003] Telephone (office):  
Facsimile:  E-mail: 
 
PTC Clinical Program Scientist   
PTC Therapeutics, Inc. [ADDRESS_386687] South Plainfield, NJ [ZIP_CODE] [LOCATION_003] Telephone (office):  
Facsimile:  
E-mail:  

Protocol Number PTC1240- GD-030- DMD [ADDRESS_386688] read the protocol document and, on behalf of my institution, agree to comply with the 
protocol and all applicable regulations.  
 
  
 
 
 
Principal  Investigator  [INVESTIGATOR_314173]:  
Address:  
City:  
State/Province:  
Country:  
Phone:  
Fax: 
E-Mail:  
 
 
Protocol Number PTC1240- GD-030-DMD 28 January 2016  
Versio n 2.0  
PTC Therapeutics, Inc. -  Confidential  
Page 5 of 63  TABLE OF CONTENTS  
1. OVERVIEW
 ................................................................................................................................................................................ 
10 
2. BACKGROUND
 ................................................................................................................................................................................ 
12 
2.1. DISEASE  INDICATION
 ..................................................................................................................................................................................................... 
12 
2.2. ATALUREN  (PTC124®)
 ................................................................................................................................................................ 
[ADDRESS_386689]
 ................................................................................................................................................................................ 
19 
6.1. STUDY DRUG SUPPLY
 ..................................................................................................................................................................................................... 
19 
6.1.1.  Study Drug Packaging and Labeling
 ........................................................................................................................................................... 
19 
6.1.2.  Study  Drug  Storage
 ........................................................................................................................................................... 
19 
6.1.3.  Study  Drug  Dispensing
 ........................................................................................................................................................... 
19 
6.1.4.  Study  Drug  Preparation
 19 
6.1.5.  Study Drug Accountability  ................................................................................................................... 20 
6.1.6.  Overdose  Precautions
 ........................................................................................................................................................... 
20 
6.1.7.  Inadvertent Exposure and Spi[INVESTIGATOR_314174]
 ........................................................................................................................................................... 
20 
6.2. STUDY DRUG TREATMENT
 ..................................................................................................................................................................................................... 
21 
6.2.1.  Study  Drug  Dosing
 ........................................................................................................................................................... 
21 
6.2.2.  Duration of Treatment
 ........................................................................................................................................................... 
21 
6.2.3.  Schedule  of Administration
 ........................................................................................................................................................... 
21 
6.2.4.  Instructions for Delays  in Dosing
 ........................................................................................................................................................... 
22 
6.3. SAFETY MONITORING AND STUDY DRUG DOSE  INTERRUPTION /MODIFICATION
 ..................................................................................................................................................................................................... 
22 
6.3.1.  Laboratory Abnormalities and Adverse Events Requiring Evaluation and 
Potential Drug  Interruption/Modification
 22 
6.3.2.  Evaluation of Adverse Events or  Laboratory  Abnormali ties
 ........................................................................................................................................................... 
23 
Protocol Number PTC1240- GD-030-DMD 28 January 2016  
Versio n 2.0  
PTC Therapeutics, Inc. -  Confidential  
Page 7 of 63  6.3.3.  Instructions  for Resuming Study  Drug  Administration  after  an Interruption for Safety  Concerns
 ........................................................................................................................................................... 
23 
6.3.4.  Instructions  for Discontinuation of Study  Drug  Administration  for Safety  Concerns
 ........................................................................................................................................................... 
24 
7. CONCOMITANT AND SUPPORTIVE THERAPY
 ................................................................................................................................................................................ 
25 
7.1. CONCOMITANT  MEDICATIONS
 ..................................................................................................................................................................................................... 
25 
7.1.1.  Corticosteriods
 ........................................................................................................................................................... 
25 
7.1.2.  Nephrotoxic  Medications
 ........................................................................................................................................................... 
25 
7.2. NON-DRUG THERAPY
 ..................................................................................................................................................................................................... 
26 
7.2.1.  Physical  Therapy
 ........................................................................................................................................................... 
26 
7.2.2.  Hydration ........................................................................................................................................................... 
26 
7.2.3.  Dietary  Restrictions
 ........................................................................................................................................................... 
26 
Protocol Number PTC1240 -GD-030-DMD 28 January 2016  
Version 2.0  
 
PTC Therapeutics, Inc. -  Confidential  
Page 8 of 63  8. SCHEDULE OF EVENTS AND  STUDY  PARAMETERS  .......................................................................... 27 
8.1. SCHEDULE  OF EVENTS  ..................................................................................................................................................... 27 
8.2. EXPLANATION OF  STUDY PROCEDURES ..................................................................................................................... 28 
8.2.1.  Study  Visits  ..................................................................................................................................... 28 
8.2.2.  Informed Consent  ........................................................................................................................... 28 
8.2.3.  Clinical/Medication  History  .......................................................................................................... 28 
8.2.4.  Vital Signs  ...................................................................................................................................... 28 
8.2.5.  Height, Weight, and Physical Examination .................................................................................... 28 
8.2.6.  Confirmatory  Gene  Sequencing ..................................................................................................... 29 
8.2.7.  Central  Laboratory  Assessments ................................................................................................... 29 
8.2.8.  12-Lead ECG  .................................................................................................................................  29 
8.2.9.  Timed  Function Tests  ..................................................................................................................... 30 
8.2.10.  North Star  Ambulatory  Assessment  ........................................................................................... 30 
8.2.11.  Pharmacokinetic  Assessment  .................................................................................................... 30 
8.2.12.  Palatability  Questionnaire  ........................................................................................................ 30 
8.2.13.  Ataluren  Administration  ............................................................................................................ 30 
8.2.14.  Adverse  Events  .......................................................................................................................... 30 
8.2.15.  Concomitant  Medications  .........................................................................................................  30 
8.3. BLOOD COLLECTION SUMMARY .................................................................................................................................. 31 
9. ADVERSE  EVENT ASSESSMENTS  ............................................................................................................. 32 
9.1. ADVERSE  EVENT DEFINITIONS  ..................................................................................................................................... 32 
9.1.1.  Adverse  Events  ............................................................................................................................... 32 
9.1.2.  Serious Adverse  Events  (SAEs) ...................................................................................................... [ADDRESS_386690] /INDEPENDENT  ETHICS COMMITTEE  ............................................................. 45 
13.3. INFORMED  CONSENT /ASSENT  ....................................................................................................................................... [ADDRESS_386691]  SELECTION  ........................................................................................................................................................ 50 
14.1.1. General  ..................................................................................................................................... 50 
14.1.2. Inclusion of Minors  ................................................................................................................... 50 
14.1.3. Reproductive  Considerations  .................................................................................................... 51 
14.1.4. Prior and Concomitant  Therapi[INVESTIGATOR_014]  ............................................................................................. 51 
14.2. TREATMENT  RATIONALE  ................................................................................................................................................ 52 
14.2.1. Ataluren Schedule and Dose  Selection  ...................................................................................... 52 
14.2.2. Duration of Therapy  .................................................................................................................. 53 
14.2.3. Selection of  Endpoint  Measures  ................................................................................................ 53 
14.2.4. Safety  Monitoring  ...................................................................................................................... 54 
15. BENEFITS  AND RISKS  .................................................................................................................................. 55 
15.1. BENEFITS AND RISKS: NON-CLINICAL  ...................................................................................................................... 55 
15.2. BENEFITS AND RISKS: CLINICAL  .................................................................................................................................  55 
15.3. BENEFIT /RISK CONCLUSIONS ........................................................................................................................................ [ADDRESS_386692] OF TABLES  
TABLE  1: SUGGESTED DAILY  DOSING SCHEDULE ..................................................................................................................... 22 
TABLE  2: SCHEDULE OF  EVENTS  ..................................................................................................................................................... 27 
TABLE  3: RELATIONSHIP OF STUDY DRUG TO ADVERSE  EVENT  .......................................................................................... 35 
TABLE  4: GRADING OF ADVERSE  EVENT  SEVERITY  ................................................................................................................. 36 
TABLE  5: INVESTIGATIONAL SITE REQUIREMENTS FOR REPORTING ADVERSE  EVENTS  .............................................. [ADDRESS_386693]  
AE Adverse event(s)  
ALT  Alanine aminotransferase  
AR Accumulation Ratio  
AST  Aspartate aminotransferase  
ATC  Anatomical -Therapeutic -Chemical  
AUC 0-t Area under the plasma concentration time curve from time zero to the time 
of last quantifiable concentration  
AUC 0-[ADDRESS_386694] disc read -only memory  
CF Cystic fibrosis  
CFR  Code of Federal Regulations  
cGMP  Current Good Manufacturing Practices  
CK Creatine kinase  
CI Confidence interval  
CL/F  Apparent clearance  
CLd/F  Apparent distribution clearance  
Cmax Maximum observed plasma concentration  
CRO  Contract research organization  
CT Computed tomography  
CTCAE  Common Terminology Criteria for Adverse Events  
Ctrough@6h  Concentration at the end of the first (morning) dosage interval  
CV%  Coefficient of variation  
DLT  Dose -limiting toxicity  
DMC  Data monitoring committee  
DMD  Duchenne muscular dystrophy  
DNA  Deoxyribonucleic acid  
ECG  Electrocardiogram  
eCRF  Electronic case report form  
EDC  Electronic data capture  
ET Early termination  
EU European Union  
FDA  Food and Drug Administration  
GCP  Good Clinical Practices  
GFR  Glomerular filtration rate  
GGT  Gamma -glutamyl transferase  
HPLC -MS/MS  High performance liquid chromatography -mass spectrometry  
IB Investigator’s Brochure  
ICH International Conference on Harmonisation  
ICJME  International Committee of Medical Journal Editors  
Protocol Number PTC1240- GD-030-DMD 28 January 2016  
Version 2.0  
PTC Therapeutics, Inc. -  Confidential  
Page 9 of 63   
Abbreviation  Definition  
ICTRP  International Clinical Trials Registry Platform  
IRB/IEC  Institutional Review Board/Independent Ethics Committee  
IV Intravenous  
ka Rate constant of absorption  
LOQ  Limit of quantitation  
MedDRA  Medical Dictionary for Regulatory Activities  
MMA  Methylmelonic acidemia  
MRI  Magnetic resonance imaging  
mRNA  Messenger ribonucleic acid  
NCA  Non-compartmental analysis  
nmDMD  Nonsense mutation Duchenne muscular dystrophy  
nmCF  Nonsense mutation cystic fibrosis  
NSAA  North Star Ambulatory Assessment  
OAT1  Organic anion transporter 1  
OAT3  Organic anion transporter 3  
OATP1B3  Organic anion transporting polypeptide 1B3  
PD Pharmacodynamic(s)  
PIP Pediatric Investigation Plan  
PK Pharmacokinetic(s)  
popPK  Population PK  
PTC124  Ataluren  
SAS Statistical Analysis System  
SAE  Serious adverse event  
t½ Terminal half -life 
TEAE  Treatment -emergent adverse event  
TFTs  Timed function tests  
TID 3 times per day  
tmax Time of maximum observed plasma concentration  
UGT  Uridine diphosphate glucuronosyltransferase  
UGT1A9  Uridine diphosphate glucuronosyltransferase 1 family, polypeptide A9  
US [LOCATION_002]  
Vc/F  Apparent central volume of distribution  
Vp/F  Apparent peripheral volume of distribution  
WHODRUG  World Health Organization Drug Dictionary  
Protocol Number PTC1240- GD-030-DMD 28 January 2016  
Version 2.0  
PTC Therapeutics, Inc. -  Confidential  
Page 10 of 63   
1. OVERVIEW  
Duchenne muscular dystrophy (DMD) is a disabling and life -threatening X -linked genetic 
disorder [ Worton 2001, Khurana 2003 ] caused by [CONTACT_314204], a protein 
that stabilizes muscle cell membranes [ Lapi[CONTACT_92256] 2004]. Due to muscle fragility, boys with DMD 
develop muscle weakness that leads to deterioration of ambulation, wheelchair dependency, and 
eventual respi[INVESTIGATOR_314175] 15 to 22 years of age [ Brooke 1989, 
McDonald 1995, Worton 2001]. Only chronic administration of corticosteroids has slowed progression of DMD.  However, corticosteroids do not address the underlying cause of DMD, are typi[INVESTIGATOR_314176], and are not always employed. There is no current therapy for the underlying cause of DMD. In approximately 13% of boys with DMD, the causative defect in the dystrophin gene is a nonsense mutation that truncates dystrophin protein production by [CONTACT_314205] a premature stop codon into the dystrophin messenger ribonucleic acid 
(mRNA) [Dent 2005 ]. Nonsense mutation (nm) DMD is estimated to affect approximately 1,700 
boys in the [LOCATION_002] (US) and approximately 2,200 boys in Europe [Hirawat 2004a, Hirawat  
2004b].  
Ataluren is an orally bioavailable, investigational new drug that promotes ribosomal readthrough 
of premature stop codons [ Welch 2007, Du 2008, Wang 2010, Goldmann 2011, Tan 2011, 
Kayali 2012]. In reporter assays, as well as in nonclinical models of genetic disease, ataluren 
demonstrates the ability to specifically and selectively enable ribosomal readthrough of mRNA containing a premature stop codon, inducing production of protei n that localizes to the 
appropriate cellular location and is functionally active [ Welch 2007, Du 2008, Wang 2010, 
Goldmann 2011, Tan 2011, Kayali 2012]. In vitro and in vivo studies in nmDMD have shown that ataluren can restore production of the missing dystrophin [ Welch 2007, Kayali 2012].  
Ataluren (Translarna) is currently available in Europe and Israel for treatment of nmDMD in 
patients older than 5 years. 
Ataluren has been administered to patients with nonsens e mutation cystic fibrosis (nmCF) as 
young as 6 years of age, patients with nmDMD as young as 5 years of age, and patients with 
nonsense mutation methlymelonic acidemia (nmMMA) as young as [ADDRESS_386695] been apparent in the activity or safety profiles of ataluren in children relative to adults. Although patients <[ADDRESS_386696] not been included in clinical studies, chronic toxicology studies in weanling rats and dogs support dosing of pediatric patients as young as  
2 year s of age. Refer to the Ataluren Investigator’s Brochure (IB) for current information on use 
in pediatric patients.  
This protocol describes a Phase 2, multiple -dose, open- label study evaluating the safety, 
pharmacokinetics (PK), and pharmacodynamics (PD) of ataluren in patients aged ≥2 to <[ADDRESS_386697] and tolerable dose in this age group, particularly sinc e 
ataluren is dosed by [CONTACT_8497]. The study will include a 4- week screening period, a 4- week study 
period, and a 48 -week extension period for patients who complete the 4- week study period (52 
weeks total treatment). The objective of the extension period is to assess the long -term safety of 
chronic administration of ataluren in this patient  population. 
Protocol Number PTC1240- GD-030-DMD 28 January 2016  
Version 2.0  
PTC Therapeutics, Inc. -  Confidential  
Page 11 of 63   
The primary objective of this study is to evaluate the safety of ataluren as measured by [CONTACT_24975], 
frequency, severity, timing, and relationship to study drug of treatment -emergent adverse events 
(TEAEs), laboratory abnormalities, and electrocardiograms (ECGs).  
The secondary objectives are to determine the plasma PK of ataluren in patients aged ≥2 to  
<5 years old with nmDMD, to monitor proximal muscle functi on using timed function tests 
(TFTs), to monitor physical function using the North Star Ambulatory Assessment (NSAA), to 
determine the effect of ataluren on weight, height, and body mass index (BMI), and to assess the palatability of ataluren.  
This study provides ongoing safety review during open- label ataluren treatment. Furthermore, a 
planned interim safety analysis will be conducted by [CONTACT_82571] (DMC) when all patients have completed 12 weeks of treatment and additionally a s needed.  
Protocol Number PTC1240- GD-030-DMD 28 January 2016  
Version 2.0  
PTC Therapeutics, Inc. -  Confidential  
Page 12 of 63   
2. BACKGROUND 
 
2.1. Disease  Indication  
DMD is an X- linked disorder caused by [CONTACT_314204], a protein that is 
critical to the structural stability of myofibers in skeletal, diaphragmatic, and cardiac muscle 
[Worton 2001, Khurana 2003]. The prevalence is estimated at approximately 13,000 males in the 
US and approximately 17,000 boys in the European Union (EU) [Hirawat 2004a, 
Hirawat 2004b].  
Dystrophin is a high- molecular -weight cytoskeleton protein localized at the inner surface of the 
muscle membrane [ Worton 2001]. It is part of a dystrophin- glycoprotein complex that also 
includes dystroglycan and sarcoglycans. This complex provides a bridge across the muscle membrane in which dystrophin couples actin in the cytoplasm with dystroglycan. Dystrophin 
deficiency destabilizes the dystrophin -glycoprotein complex, impairing localization of the 
dystroglycan and sarcoglycans to the muscle membrane, and compromising the structural 
integrity of the membrane. The absence of normally functioning dystrophin results in sarcolemmal breakdown, calcium ion influx, phospholipase activation, oxidative muscle injury, and, ultimately, myonecrosis. As muscle damage progresses, connective tissue and fat replace muscle fibers.  
In patients with DMD, the age at which the earliest sign or symptom of the disease is noted 
ranges from infancy to approximately 6 years old [ Ciafaloni 2009]. Initial signs and symptoms of 
DMD include lordosis, a waddling gait, and the Gowers’ sign (a characteristically abnormal 
method of rising from a supi[INVESTIGATOR_99682] a standing position) [ Brooke 1989, McDonald 1995, Boland 
1996, Worton 2001]. Inexorable progressive weakness is seen, particularly in the proximal musculature. Ambulation becomes increasingly abnormal.  By [CONTACT_14898] [ADDRESS_386698] difficulty rising from the floor and ascendi ng stairs and they often fall while walking. Boys 
with the disease spend less time walking and walk more slowly than healthy boys  
[McDonald 2005a ], and are significantly less active than normal boys of similar age [ McDonald 
2002, McDonald 2005b]. By [ADDRESS_386699] frequent cardiac abnormality is sinus tachycardia and heart rate variability, occurring from childhood and persisting throughout life [ Finsterer 2003, Gulati 
2005]. Pulmonary function is usually normal before 10 years of age and is well maintained into adolescence in bo ys receiving corticosteroids [ Mendell 1989, Griggs 1991, Phillips 2001, 
Tangsrud 2001, Biggar 2001, Biggar 2006]. Later in adolescence, cardiac and diaphragmatic muscles become progressively weaker and patients require treatment for cardiac insufficiency and ventilatory support. Patients usually die of cardiac  or pulmonary failure by 
15 to 22 years of age [ Brooke 1989, McDonald 1995, Simonds 1998, Worton 2001, Eagle 2002].  
Presently, ataluren is the only therapy available to restore dystrophin protein production and 
preserve muscle function. The current standard of care is corticosteroids, which do not address the underlying cause of the disease and are not typi[INVESTIGATOR_314177] 5 years old. 
Protocol Number PTC1240- GD-030-DMD 28 January 2016  
Version 2.0  
PTC Therapeutics, Inc. -  Confidential  
Page 13 of 63  2.2. Ataluren  (PTC124®)  
 
2.2.1.  Therapeutic Concept  
Among the several types of disease -causing mutations, a nonsense mutation is a single -point 
alteration in one of the nucleotides of deoxyribonucleic ac id (DNA) that, when copi[INVESTIGATOR_314178], 
is interpreted as a stop signal by [CONTACT_314206]. The presence of 
such a premature stop signal within the protein- coding region of the mRNA for dystrophin 
signals the ribosomes to halt pr oduction of the protein before the full -length protein is 
completed. The resulting truncated dystrophin is too short to serve its necessary function and 
causes disease.  It is estimated that approximately 10 -15% of all boys with DMD have a 
nonsense mutation as the basis for the disorder [ Dent 2005], resulting in a prevalence of 
approximately 1,700 boys in the US and approximately 2,200 boys in Europe. 
It has been known for some time that drugs with translation- modifying mecha nisms of action, 
such as the aminoglycoside antibiotics (eg, gentamicin), can ameliorate the effects of nonsense 
mutations in experimental systems. By [CONTACT_314207], such agents permit the ribosomes to reinterpret the nonsense mutation stop signal in mRNA such that they can move through the obstruction by [CONTACT_314208] a full -length functional protein. In experimental animal systems and in pi[INVESTIGATOR_314179], treatment with high conc entrations of gentamicin has restored production of functional 
dystrophin [Barton -Davis 1999, Politano 2003]. Similarly, nonclinical and clinical studies in 
cystic fibrosis (CF) have demonstra ted restoration of the CF transmembrane conductance 
regulator, the epi[INVESTIGATOR_314180] [ Clancy 2001, Du 2002, 
Wilschan ski 2003]. Data suggest that the geometry of mRNA and associated initiation-  
termination proteins is critically different at a premature stop compared with a normal stop. This may explain why a drug can permit the ribosomes to selectively read through the premature stop codon, but will not allow the ribosomes to read through the normal stop codon at the end of the 
mRNA protein -coding region [ Sachs 2000, Welch 2000 , Amrani 2004]. Because serious renal 
and otic toxicities and the need for parenteral administration preclude the long- term clinical use 
of gentamicin, there has been considerable interest in the identification of safer and more conveniently a dministered, low -molecular -weight, synthetic compounds with the ability to 
promote readthrough of disease -causing nonsense mutations.  
PTC Therapeutics is a biopharmaceutical company involved in the discovery and development of new therapi[INVESTIGATOR_314181]. Based on the clear medical need in dystrophinopathy and 
other genetic disorders, and the unacceptable toxicity that would be associated with chronic systemic aminoglycoside use, scientists at the company have conducted a drug discovery progr am with the objective of finding and developi[INVESTIGATOR_314182]. A high- throughput screening program identified sets of novel, non-  
aminoglycoside chemical structures that selectively induce ribosomal readthrough of premature stop codons in mRNA. Chemical optimization, pharmacologic characterization, and toxicological evaluation have led to identification of ataluren as an orally bioavailable, small 
molecule with potential clinical utility in treating genetic disor ders through induction of 
readthrough of nonsense mutations and production of full -length, functional proteins [ Welch  
2007, Du 2008]. In the subset of patients whose disease is mediated by a nonsense mutation, 
ataluren may offer a definitive therapy by [CONTACT_314209] -threatening genetic disorders.
Protocol Number PTC1240- GD-030-DMD 28 January 2016  
Version 2.0  
PTC Therapeutics, Inc. -  Confidential  
Page 14 of 63   
2.2.2.  Chemical  Description  
Ataluren is a new chemical entity with a chemical formula of C 15H9FN 2O3 and a molecular 
weight of 284.2 Daltons. Ataluren is a Biopharmaceutical Classification System Case 2 
compound, possessing low aqueous solubility (<31 µ g/mL) but high permeability across 
gastrointestina l epi[INVESTIGATOR_2130], consistent with its high oral bioavailability.  
 
2.2.3.  Clinical Studies  
In total, >[ADDRESS_386700] been exposed to ataluren in Phase 1 [ Hirawat  
2007], Phase 2 [ Kerem 2008 , Sermet -Gaudelus 2010, Wilschanski 2011, Finkel 2013] and Phase 
3 [Kerem 2014, Bushby 2014] clinical studies. Refer to the Ataluren IB for a detailed 
presentation of safety, efficacy, and PK data from these clinical studies.  
Protocol Number PTC1240- GD-030-DMD 28 January 2016  
Version 2.0  
PTC Therapeutics, Inc. -  Confidential  
Page 15 of 63   
3. STUDY OBJECTIVE AND ENDPOINTS  
3.1. Primary Objective  
The primary objective of this study is to:  
• Evaluate the safety of ataluren as measured by [CONTACT_24975], frequency, severity, timing, and 
relationship to study drug of TEAEs, laboratory abnormalities and ECGs  
 
3.2. Secondary  Objectives  
The secondary objectives of this study are to:  
• Evaluate the plasma PK of ataluren in patients aged ≥2 to <5 years old with nmDMD 
• Assess proximal muscle function using TFTs  
• Assess change in physical function using the  NSAA 
• Determine the effect of ataluren on weight, height, and BMI  
• Assess the palatability of  ataluren  
3.3. Primary  Endpoint  
The primary endpoints of this study are:  
• Overall safety profile in terms of the type, frequency, severity, timing, and relationship to study therapy of any adverse events (AEs) or abnormalities of physical findings, laboratory tests, or ECGs  
• Occurrence of any dose -limiting toxicities  (DLTs)  
• Drug discontinuations due to AEs 
• Serious adverse events  (SAEs)  
3.4. Secondary  Endpoints  
The secondary endpoints are:  
• Pharmacokinetic parameters (t
max, t1/2, Cmax, Ctrough@6h , AUC 0-10), CL/F, and Vc/F based on 
frequent blood sampling for PK on Days 1 and 28 of ataluren treatment. On each of these days, blood sa mples for ataluren concentration assessments will be collected immediately 
pre-dose and at specified time points following the morning, midday, and evening doses. 
Ataluren  concentrations  in plasma  will be analyzed  using a validated  HPLC -MS/MS  
method. 
• TFTs (time to walk/run 10 meters, time to climb 4 stairs, time to descend 4 stairs, and 
time to stand up from a supi[INVESTIGATOR_84740])  
• NSAA 
• Changes in body weight, height, and BMI  
• Ataluren palatability characteristics as determined by a parent/caregiver  questionnaire  
Protocol Number PTC1240- GD-030-DMD [ADDRESS_386701] to review in the 
case of a Good Clinical Practice (GCP) audit or a regulatory authority inspection. Any questions regarding a patient’s eligibility should be discussed with the PTC Therapeutics medical monitor or designee prio r to enrollment. 
 
4.2. Inclusion Criteria  
Patients must meet all of the following conditions to be eligible for enrollment into the study:  
 
General inclusion criteria  
1. Evidence  of signed and dated informed consent document(s) indicating that the study candidate  
(and/or a parent/legal guardian) has been informed of all pertinent aspects of the study. Note: As 
all study candidates are considered children under local regulation, at least one parent or legal 
guardian must provide written consent prior to initiation of study -related procedures, in 
accordance with local regulation, and the study candidate may be required to provide written assent. The rules of the responsible institutional review board/independent ethics committee 
(IRB/IEC) regarding whether one or bot h parents must provide consent and the appropriate ages 
for obtaining consent and assent from the patient should be  followed.  
2. Males ≥2 to <5 years of  age 
3. Body weight ≥12 kg 
4. Willingness and ability to comply with scheduled visits, drug administration plan, study 
procedures, and study restrictions.  
5. No clinically significant abnormality based upon laboratory assessments during the screening period, in the opi[INVESTIGATOR_689]; good general health, as determined during the screening period by [CONTACT_44059] (including vital sign measurements).  
DMD inclusion criteria  
6. Diagnosis of DMD based on an elevated serum CK and genotypic evidence of dystrinopathy. Medical documentation of phenotypic evidence of dystrophi nopathy needs 
to be provided upon request by [CONTACT_314210]. 
7. Documentation of the presence of a nonsense mutation in at least 1 allele of the  dystrophin 
gene.  
8. Verification that a blood sample has been drawn for sequencing of the dystr ophin gene. 
Note: A patient who has written documentation of a nonsense mutation as the cause of dystrophinopathy need not wait for confirmatory results to start study  drug. 
Protocol Number PTC1240- GD-030-DMD 28 January 2016  
Version 2.0  
PTC Therapeutics, Inc. -  Confidential  
Page 17 of 63   
4.3. Exclusion Criteria  
The presence of any of the following conditions will exclude a patient from study enrollment: 
General exclusion criteria 
1. Patients participating in any drug or device clinical investigation or having received  an 
investigational drug within 3 months prior to Visit 1 (Screening) or who anticipate 
participating in any other drug or device clinical investigation or receiving any other investigational drug within the duration of this  study. 
2. Expectation of a major surgical procedure during the study period.  
3. Prior or ongoing medical condition, medical history, physic al findings, or laboratory 
abnormality that, in the Investigator’s opi[INVESTIGATOR_1649], could adversely affect the safety of the patient, or makes it unlikely that the course of study drug administration or follow -up 
would be completed, or could impair the assessment of study results.  
4. Known hypersensitivity to any of the ingredients or excipi[INVESTIGATOR_65877] (polydextrose, polyethylene glycol 3350, poloxamer 407, mannitol 25C, crospovidone XL10, hydroxyethyl cellulose, vanilla, colloidal silica, or magnesium  stearate).  
Drug therapi[INVESTIGATOR_014]  
5. Ongoing use of the following drugs:  
Drugs metabolized by [CONTACT_097]2C8 (eg, paclitaxel) or CYP2C9 (eg, coumarin anticoagulants 
[warfarin], phenytoin, or tolbutamide)  
Drugs that are inhibitors of breast cancer resistant protein (BCRP) (eg, cyclosporine, 
eltrombopag, geftinib)  
Drugs that are substrates of UGT1A9 (eg, propofol, mycophenolate mofetil), OAT1, 
OAT3, or OATP1B3 (eg, oseltamivir, acyclovir, captopril, furosemide, bumetanide, valsartan, pravastatin, rosuvastatin, atorvastatin, pi[INVESTIGATOR_2830])  
Drugs  that are general inhibitors of UGT (eg, probenecid, valproic acid)  
 
6. Treatment with systemic aminoglycoside antibiotics within [ADDRESS_386702] 12 patients will be enrolled. Patients will be recruited from dystrophinopathy 
populations who receive care or are referred for evaluation at the investigational site. The principal Investigator [INVESTIGATOR_11637]- investigator will disc uss the possibility of participation directly with 
parent(s)/legal guardian in the  clinic.  
 
5.2. Screening and Study Drug  Dispensation  
The Investigator must inform each parent/legal guardian and study candidate of the nature of the study, explain the potential risks, and obtain written informed consent/assent from the parent(s)/legal guardian and/or study candidate (as required by [CONTACT_427]) prior to performing any study- related screening procedures. Once written informed consent/assent has 
been obtained, a site representative should access Medrio (the electronic data capture [EDC] system) to indicate that a candidate is being screened. The user will need to supply the EDC 
system with the required information to permit study drug dispensation. Refer to the CRF 
Completion Guidelines for additional details.  
Using forms in the Medrio system, the EDC system will document all screening that has occurred. The Medrio Randomization module will be used to assign kit numbers and email notifications for shipment of i nvestigational drug kits. Forms in the Medrio system will be used 
to track receipt of the drug shipment at the site.  
Protocol Number PTC1240- GD-030-DMD [ADDRESS_386703] are manufactured under 
current Good Manufacturing Practices (cGMP) conditions. The formula tion includes matrix and 
suspending agents, surfactants, and various excipi[INVESTIGATOR_314183].  
Ataluren granules are packaged in aluminum foil, child- resistant sachets and supplied in dose 
strengths containing 125 or 250 mg of the a ctive drug substance.  
Ataluren will be supplied free of charge to the investigational site by [CONTACT_314211]/caregivers.  
 
6.1.1.  Study Drug Packaging and  Labeling  
Sachets and cartons will be color -coded to indicate dosage strength (125 mg – yellow, 
250 mg -  pi[INVESTIGATOR_8745]). Labels will be provided in appropriate languages as required by [CONTACT_314212]. The content of the labeling will be in accordance with local 
regulatory specifications and requir ements.  
6.1.2.  Study Drug  Storage  
Sachets of ataluren will be shipped to the investigational sites, and stored and monitored at room temperature (~15 to 30°C). The available stability data from representative samples support the use of the drug product for [ADDRESS_386704] not be used outside the context of this protocol. Under no circ umstances should the Investigator or site personnel supply ataluren to 
other investigators or clinics, or allow the ataluren supplies to be used other than as directed by [CONTACT_3181]. 
 
6.1.3.  Study Drug  Dispensing  
Dosing of ataluren will be based on milligrams of drug per kilogram of patient body weight 
assessed every 12 weeks and will be calculated to allow for dosing with the appropriate dose 
strengths (125 mg or 250 mg). 
The clinic staff (eg, pharmacist or other qualified person) will be responsibl e for dispensing 
ataluren at the beginning of the study and every 12 weeks during the extension period according 
to the instructions in the study manual. 
 
6.1.4.  Study Drug  Preparation  
Once at the investigational site and/or with the patient/caregiver, ataluren s achets should be 
stored at room temperature, away from the reach of children, until the time of reconstitution. The appropriate sachet strength will be used to prepare each dose. The full contents of each sachet should be mixed with at least 30 mL (1 ounce ) of liquid, or [ADDRESS_386705] administered imme diately after preparation. The prepared dose should 
be discarded if not consumed within 3 hours (if kept at room temperature) or within 24 hours of preparation (if kept refrigerated).  
Detailed written drug mixing and dosing instructions will be provided to the patient/caregiver 
when ataluren supplies are dispensed. A copy of these instructions will be maintained in the 
Investigator site study file.  
 
6.1.5.  Study Drug  Accountability  
The Investigator and/or the responsible site personnel must maintain accurate records of the receipt of all ataluren shipped by [CONTACT_314213], including, but not limited to, the date received, lot number, amount received, and the disposition of all ataluren. Current reconciliation and dispensing records m ust also be maintained that include the date and amount 
of ataluren dispensed, relevant batch numbers, and patient’s assigned study number. Caregivers 
should return all unused sachets of ataluren to the investigational site at the end of each 12- week 
treatment interval for inventory. The eCRF will serve as the source document for drug supply to 
the patients and will document the return of any unused drug for compliance assessments.  
Depending upon the decision of PTC Therapeutics, unused clinical supplies must be destroyed or 
returned to PTC Therapeutics (or its designee) after the study is completed and drug accountability has been verified by [CONTACT_2037]. Records documenting the date of study drug destruction or shippi[INVESTIGATOR_007], relevant batch numbers, and amount destroyed or shipped should be kept in the investigational site study file.  
The Medrio EDC system will be used to track drug accountability.  
 
6.1.6.  Overdose Precautions  
For any patient experiencing an overdose (see Section 9.1.1 for the definition of overdose), 
observation for any symptomatic side effects should be instituted, and vital signs and biochemical and hematological parameters should be followed closely (consistent with the protocol or more frequently, as needed). Appropriate supportive management to mitigate adverse 
effects should be initiated. Pending the acquisition of sufficient human experience with the drug, use of gastric lavage or induction of emesis is not specifically recommended or contraindicated.  
The PT C Therapeutics medical monitor must be contact[CONTACT_314214]. Under 
applicable regulations, overdosing may be considered a SAE and should be reported accordingly (see Section s 9.1.1 and 9.1.2) . 
 
6.1.7.  Inadvertent Exposure and Spi[INVESTIGATOR_314184], ataluren does not appear to be acutely toxic or 
genotoxic at levels that are likely to result from inadvertent exposure to the contents of the 
packet, i f opened. Based on general experience with the drug during manufacturing, it does not 
appear that exposure to formulated ataluren is likely to be irritating to skin or eyes. However, personnel handling the drug should use reasonable precautions to avoid ey e contact, skin contact,  
Protocol Number PTC1240- GD-030-DMD 28 January 2016  
Version 2.0  
PTC Therapeutics, Inc. -  Confidential  
Page 21 of 63   
inhalation, or ingestion of the material in the packets. Refer to the Ataluren IB for current 
information on inadvertent exposures and spi[INVESTIGATOR_283641]. 
 
6.2. Study Drug  Treatment  
 
6.2.1.  Study Drug  Dosing  
Dosing of ataluren will be based on milligrams of drug per kilogram of patient body weight 
assessed every 12 weeks. All patients will receive approximately 10, 10, 20 mg/kg ataluren 3 times daily (TID) for 4 weeks during the PK portion and for 48 weeks during the extension period. 
 
6.2.2.  Duration of  Treatment  
The study duration will be 4 weeks during the PK portion and 48 weeks during the extension period (52 weeks total). Initial data assessment and reporting will be after all patients complete first 4 weeks (safety and PK) to sat isfy Pediatric Investigation Plan (PIP) requirements and an 
additional report will be issued after completion of 48 weeks extension). The study may be terminated by [CONTACT_314215], eg, the clinical development of ataluren in dys trophinopathy is discontinued. 
 
6.2.3.  Schedule of  Administration  
As noted in Table 1 , 3 doses should be taken per day – the 1st dose in the morning, the 2nd dose 
during the middle of the day (midday), and the 3rd dose in the evening. Intervals for dosing 
should be ~6 hours ( ±1 hour) between morning and midday doses, ~6 hours ( ±1 hour) between 
midday and evening doses, and ~12 hours ( ±1 hour) between evening doses and the morning 
dose on the next day.  
Protocol Number PTC1240- GD-030-DMD 28 January 2016  
Version 2.0  
PTC Therapeutics, Inc. -  Confidential  
Page 22 of 63   
Table 1: Suggested Daily Dosing Schedule  
 
Dose Designation  Example Dosing Times  
Morning  ~7:00 AM –  0700 hours ( ±1 hour)  
 ↑ 
~6 hours  
↓ 
Mid-day ~1:00 PM –  1300 hours ( ±1 hour)  
 ↑ 
~6 hours  
↓ 
Evening  ~7:00 PM –  1900 hours ( ±1 hour)  
 ↑ 
~12 hours  
↓ 
Next Day Morning  7:00 AM – 0700 hours ( ±1 hour)  
 
6.2.4.  Instructions for Delays in  Dosing  
Dosing delays should be handled as follows:  
• If there is a delay in the administration of ataluren of <3 hours after the morning or midday 
doses or <6 hours after the evening dose, the planned dose should be taken with no changes 
to the subsequent dose  schedules. 
• If there is a delay in the administration of ataluren of >3 hours after the morning or midday 
doses or >6 hours after the evening dose, the planned dose should not be taken and patients 
should resume their usual dosing schedule.  
 
6.3. Safety Monitoring and Study Drug Dose  Interruption/Modification  
 
6.3.1.  Laboratory Abnormalities and Adverse Events Requiring Evaluation  and 
Potential Drug  Interruption/Modification  
Patients must be monitored closely for AEs or laboratory abnormalities during the course of the 
study. 
For AEs or laboratory abnormalities, the Investigator will use judgment in determining whether 
the event or abnormality is clinically significant, whether diagnostic evaluation is warranted, and whether potential interruption of study drug treatment is appropriate. In general, life -threatening 
(Grade 4) or severe (Grade 3) AEs or laboratory abnormalities should be considered clinically significant, although recurrent or persistent moderate events (Grade 2) may also be considered clinically significant in ce rtain circumstances. Reference should be made to the Common 
Terminology Criteria for Adverse Events (CTCAE), Version 4.0 (see http://evs.nci.nih.gov/ftp1/CTCA E/CTCAE_4.03_2010- 06-14_QuickReference_5x7.pdf ) for 
grading the severity of AEs and laboratory abnormalities. 
Protocol Number PTC1240- GD-030-DMD [ADDRESS_386706] either 
the PTC Therapeutics medical monitor (or designee) to obtain guidance and to ascertain whether similar events are being seen at other investi gational sites. The PTC Therapeutics medical 
monitor should be notified of any AE or laboratory abnormality that leads to dose interruption and should be apprised of ancillary laboratory or other diagnostic findings and the evolving data from any work -up of the initial abnormality. The PTC Therapeutics medical monitor may 
suggest review of the case with gastroenterology or nephrology consultants or with other experts (either at the site or retained by [CONTACT_314216]).  
Clinical evaluations for potential he patic and renal toxicities may include the following:  
• Hepatic: The medical history, hepatitis screening results, all clinical blood values 
(particularly serum bilirubin, gamma -glutamyl transferase [GGT], a
spartate 
aminotransferase [AST], and alanine aminot ransferase [ALT] values), and all concomitant 
medications should be reviewed. Depending upon changes observed, the recommended 
diagnostic workup may include more frequent monitoring or further evaluations for viral hepatitis and immune disorders; tests for  cholelithiasis; or abdominal ultrasound, computed 
tomography (CT), magnetic resonance imaging (MRI), or other imaging methods. 
• Renal: The medical history, all clinical blood and urine renal values, serum electrolytes, medications, and potential pre - or post renal conditions should be reviewed. Depending 
upon the changes observed, recommended diagnostic workup may include further evaluations of blood or urine; tests of glomerular filtration rate (GFR), concentrating ability, or other renal functions; CT, MRI, or other imaging methods; and/or renal biopsy. Transient reversible mild (Grade 1) hypercreatinemia was seen in ~15% of patients in Study 009.  Therefore, renal function should be monitored and only if sustained (ie, >4 weeks) should dose adjustment or discontinuation be considered after discussion with the PTC Therapeutics medical monitor.  
 
6.3.3.  Instructions  for Resuming  Study  Drug  Administration  after an Interruption for 
Safety  Concerns  
In deciding whether to re -institute study drug after a dose interrupt ion for any clinically 
significant safety concern, the Investigator in consultation with PTC Therapeutics should 
consider factors such as the following:  
• Type and severity of the AE or laboratory abnormality 
• The potential causal relationship of study drug 
• The patient’s status in terms of dystrophinopathy and other health conditions  
• The ability to monitor for recurrence of the event  
For hepatic or renal events, the level of Investigator certainty that an abnormality leading to drug 
interruption is drug- related should be considered strongly in deciding if and when to re -institute 
ataluren treatment. If the Investigator considers the hepatic or renal event that led to ataluren 
interruption as probably related to ataluren, restarting ataluren is not advised. In t his case, the 
Protocol Number PTC1240- GD-030-DMD 28 January 2016  
Version 2.0  
PTC Therapeutics, Inc. -  Confidential  
Page 24 of 63  patient should be discontinued from the study (see Section 10) . If the Investigator considers the  
hepatic or renal event that prompted ataluren interruption to be possibly related or unlikely 
related to ataluren , the Investigator should use best judgment in determining whether to restart 
ataluren. If the hepatic or renal event is considered unrelated to ataluren, re- institution of ataluren 
is recommended.  
If the Investigator believes it is appropriate to do so and the PTC Therapeutics medical monitor has been consulted, ataluren may be re -initiated.  If the event was determined to be unrelated to 
ataluren, the treatment may be resumed at full dose.  Otherwise, if the drug is resumed, it should be initially re -initiated at half of the original dose.  The appropriate clinic staff should instruct the 
patient/caregiver about the revised number of study drug sachets to be used per dose according to the new schedule.  Re- challenge at half dose should be initiated only as  a bridge to full dosing. If 
a patient cannot tolerate the full dose, he/she should be discontinued from study participation. 
If further evaluation reveals that the AE that led to dose reduction was not related to the ataluren, 
the dose should be escalated to the original dose level. 
If after dose reduction, the patient experiences a recurrence of a previous abnormality that led to 
ataluren dose interruption or experiences a new occurrence of an unacceptable AE or laboratory abnormality, the Invest igator should interrupt ataluren and confer with the PTC Therapeutics 
medical monitor regarding the potential need to discontinue ataluren permanently and discontinue the patient from the study. 
6.3.4.  Instructions  for Discontinuation  of Study  Drug  Administration  for Safety 
Concerns  
Study drug should be permanently discontinued following appropriate consideration of study 
drug interruption/modification and consultation with the PTC Therapeutics medical monitor or 
designee. If permanent discontinuation of study drug is the result of an SAE, then a follow -up 
SAE report form must be completed (see Section 9.7). In the case of treatment discontinuation 
due to an AE that is not an SAE, the PTC Therapeutics medical monitor or designee should be notified (see Section 10) . In addition, details regarding the reasons for discontinuation and the 
AEs leading to the discontinuation should be recorded in the source documents and in the appropriate eCRF. T he Early Termination (ET) Visit eCRF should be completed and appropriate 
follow -up (at ~[ADDRESS_386707]) should be instituted.  
Protocol Number PTC1240- GD-030-DMD [ADDRESS_386708] drugs, tobacco products, or alcohol at any time 
during the study. 
If considered necessary for the patient’s well -being, drugs for concomitant medical conditions or 
for symptom management may be given at the discretion of the Investigator. The decision to 
authorize the use of any other drug(s) should take into account patient safety, t he medical need, 
the potential for drug interactions, the possibility for masking symptoms of a more relevant underlying event, and whether use of a concomitant medication will compromise the outcome or integrity of the study. 
Parents/caregivers should be instructed about the importance of informing the clinic staff of the 
patient’s use of any drugs or remedies (whether prescribed, over -the-counter, or illicit) before 
and during the course of the study. Information regarding all concomitant medications will  be 
collected and documented in the concomitant medication page of the eCRF. 
 
7.1.1.  Corticosteriods  
To date, corticosteroid use is the only pharmacological intervention that has demonstrated 
benefit in DMD [ Mendell 1989, Fenichel 1991a , Fenichel 1991b, Griggs 1991, Biggar 2001, 
Beenakker 2005, Biggar 2006, Pradhan 2006]. Subjects who require corticosteroid interruption, 
dose modification, or reinstitution may remain on study drug therapy.  
Co-administration of systemic corticosteroids with ataluren may cause more frequent instances 
of hypertension than does systemic corticosteroid use alone (without ataluren). However, the blood pressure data available to date are not definite about any contributory role of ataluren in development of hypertension in patients who are taking corticosteroids.  
 
7.1.2.  Nephrotoxic  Medications  
Renal abnormalities were observed in a Phase 3 trial evaluating ataluren in patients ≥[ADDRESS_386709] ic fibrosis (nmCF) who were receiving concomitant IV 
aminoglycosides and IV vancomycin (as described in the Ataluren IB). Caution should therefore 
be exercised during concomitant use of study drug and potentially nephrotoxic agents.  
In patients who require  treatment for serious infections, investigators should substitute other 
antibiotics for systemic aminoglycosides or vancomycin when clinically appropriate, if possible. If IV aminoglycosides or IV vancomycin are administered, study drug must be interrupte d during 
the course of antibiotic therapy. Patients requiring IV aminoglycoside or vancomycin therapy should be closely monitored in an appropriate setting, such as a hospi[INVESTIGATOR_307]. Investigators should be particularly vigilant with patients experiencing nausea , vomiting, diarrhea, fever, or laboratory  
Protocol Number PTC1240- GD-030-DMD 28 January 2016  
Version 2.0  
PTC Therapeutics, Inc. -  Confidential  
Page 26 of 63   
evidence of dehydration. Treatment with ataluren may be resumed no earlier than 2 days after 
administration of these antibiotics has ceased.  
In patients receiving such agents, antibiotic drug levels and serum creatinine and blood urea nitrogen (BUN) should be monitored closely as follows:  
• Creatinine and BUN should be  measured:  
o Prior to initiating IV aminoglycoside or vancomycin therapy  
o Within [ADDRESS_386710] antibiotic administration (and further 
antibiotic dosing should be based on these  results)  
o At least twice a week during the course of antibiotic treatment (if  possible)  
• Antibiotic trough levels should be  measured:  
o Within [ADDRESS_386711] antibiotic adminis tration (and further 
antibiotic dosing should be based on these  results)  
o At intervals during the course of antibiotic treatment based on clinical  need  
7.2. Non-Drug  Therapy  
 
7.2.1.  Physical Therapy  
There are neither restrictions nor prescriptions for physical therapy during the study. Sites should 
use local best practices in providing physical therapy support for patients participating in the study. 
7.2.2.  Hydration  
Because of the potential risk of renal dysfunction during periods of dehydration in patients 
receiving ataluren, it is important to encourage study patients to maintain adequate hydration throughout the study. Patients should be adequately hydrated prior to receiving any potentially nephrotoxic agents, and hydration status should be carefully monitored throughout the administration of any agent with nephrotoxic characteristics. Investigators should be particularly vigilant with patients who are experiencing nausea, vomiting, diarrhea, fever, or laboratory evidence of dehydration. 
 
7.2.3.  Dietary  Restrictions  
There are no specific dietary restrictions in the study.  
Protocol Number PTC1240- GD-030-DMD 28 January 2016  
Version 2.0  
PTC Therapeutics, Inc. -  Confidential  
Page 27 of 63   
8. SCHEDULE OF EVENTS AND STUDY PARAMETERS  
 
8.1. Schedule of  Events  
The types and timing of data to be recorded are summarized in Table 2. Please see Sectio n 8.2 
for explanations of the study procedures outlined. 
Table 2:  Schedule of  Events  
 
 
Day (±2)  
Weeks 
Visit  
Informed consent  
Clinical and medication history Vital signs  
Height Weight  
Physical examination 
Hematology  
Blood sample for gene sequencing 
c 
Biochemistryd 
Urinalysis  
12-lead ECG  
Timed function tests  
North Star Ambulatory Assessment 
Blood for ataluren PKe 
Palatability questionnaire 
Drug administration   
Screening  
-28 
-4 
1 
X 
X 
X 
X 
X X 
X 
X 
X 
X 
X  
Ataluren Treatment  
1a 28 112 196 280 364 
0 4 16 28 40 52/ETb 
[ADDRESS_386712] be done prior to ataluren dosing.  
b Patients who terminate the study early should complete all assessments required for Week 52/ET (Visit 7) and will be 
required to return 4 weeks from the final dose of study medication for the 4-Week Follow -up Visit.  
c Verification that a blood sample has b een drawn for sequencing of the dystrophin gene. A patient who has written 
documentation of a nonsense mutation as the cause of DMD need not wait for confirmatory results to start study drug as 
long as the confirmatory blood sample for gene sequencing was drawn.  
d Biochemistry laboratory assessments will include hepatic transaminases and additional parameters as specified in 
Section  [IP_ADDRESS].  
e On Days  1 and 28, blood samples  for PK assessment  will be drawn  pre-dose  and 1 (±15  min),  2 (±15  min),  4 (±30  min),  
6 (±30 min), 8 (±30 min), and 10 (±30 min) hours post -dose.  
Abbreviations : ECG = electrocardiogram, ET = early termination, PK = pharmacokinetics  
Protocol Number PTC1240- GD-030-DMD  28 January 2016  
Version 2.0   
PTC Therapeutics, Inc. -  Confidential  
Page 28 of 63  8.2. Explanation of Study  Procedures  
 
8.2.1.  Study  Visits  
 
[IP_ADDRESS].  Screening (Visit  1) 
No study- related procedures should be performed prior to the signing of the informed consent/ 
assent document(s). Thereafter, patients should undergo the initial set of screening procedures as 
noted in Tab le 2. 
Study participants will report to the clinic on the morning of each on -site visit and will remain in 
the clinic until released by [CONTACT_314217] -related procedures have been 
completed and the patient and/or parent(s)/caregiver h ave been instructed regarding drug storage, 
reconstitution, and administration. 
 
[IP_ADDRESS].  Treatment Visits  
During the treatment period, each patient will return to the clinical research facility during Week 0 (Visit 2) and Week 4 (Visit 3) for PK testing, and Week 16 (Visit 4), Week 28 (Visit  5), 
Week 40 (Visit 6), and Week 52 (Visit 7/ET). 
 
[IP_ADDRESS].  End of Treatment  
If the patient discontinues treatment prematurely, the procedures required for Week 52  
(Visit 7/ET) should be performed before the patient leaves the study and the patient should return 
for the [ADDRESS_386713] -Treatment Follow -up Visit.  
Please refer to Section 10  for further details regarding patient withdrawal procedures.  
 
8.2.2.  Informed  Consent  
The Investigator/study staff member must inform each study candidate of the nature of the study, explain the potential risks, and obtain written informed consent from the parent(s)/legal guardian and/or study candidate (as required by [CONTACT_427]) prior to performing any study- related 
screening procedures.  
 
8.2.3.  Clinical/Medication  History  
The Investigator or a qualified designee should review the patient’s clinical history, including details relating to DMD and any other medical conditions. Information regarding clinical history and current medi cations must be captured on the medical history and prior/concomitant 
medication eCRFs, respectively.  
 
8.2.4.  Vital Signs  
Vital signs (pulse rate and body temperature) will be monitored at all protocol -required study 
visits. Pulse rate determinations will be perf ormed with the patient in a sitting position after a 5-
minute rest.  
8.2.5.  Height, Weight and Physical  Examination  
Height (in cm) and weight (in kg) will be measured at all study visits.  A full physical 
Protocol Number PTC1240- GD-030-DMD  28 January 2016  
Version 2.0   
PTC Therapeutics, Inc. -  Confidential  
Page 29 of 63  examination (including evaluation of the cardiovascular syst em, chest and lungs, thyroid, 
abdomen, nervous system, skin and mucosae, musculoskeletal system, eyes, ears, nose, mouth, 
throat, spi[INVESTIGATOR_050], lymph nodes, and extremities) will be conducted at Screening (Visit 1) and 4- week 
Follow -up (Visit 8), 4 weeks after di scontinuation of study drug. 
Physical examinations may also be performed at any time during the study as clinically indicated.  
 
8.2.6.  Confirmatory Gene  Sequencing  
A blood sample for dystrophin gene sequencing will be drawn at Screening (Visit 1). The study 
manual should be referenced for collection, processing, and shippi[INVESTIGATOR_22026]. 
 
8.2.7.  Central Laboratory Assessments 
All laboratory samples will be analyzed by a central laboratory. Please refer to the study manual for instructions regarding collection, processing, and shipment of all laboratory samples. 
 
[IP_ADDRESS].  Hematology Laboratory Assessment  
Hematology laboratory assessments will include white blood cell count with differential, 
hemoglobin, hematocrit, other red cell parameters, and platelet count . These parameters will be 
measured at every protocol -specified study visit. The study manual should be referenced for 
collection, processing, and shippi[INVESTIGATOR_22026]. 
 
[IP_ADDRESS].  Biochemistry Laboratory Assessment  
Biochemistry laboratory assessments will include so dium, potassium, chloride, bicarbonate, 
blood urea nitrogen, creatinine, magnesium, calcium, phosphorus, uric acid, glucose, total 
protein, albumin, bilirubin (total, direct, and indirect), AST, ALT, GGT, CK, lactate dehydrogenase, alkaline phosphatase, total cholesterol, high- density lipoprotein, low -density 
lipoprotein, triglycerides, and cystatin C. These parameters will be measured at every protocol - 
specified study visit. The study manual should be referenced for collection, processing, and shippi[INVESTIGATOR_22026]. 
 
[IP_ADDRESS].  Urinalysis  
Urinalysis will include analysis for pH, specific gravity, glucose, ketones, blood, protein, urobilinogen, bilirubin, nitrite, and leukocyte esterase. These parameters will be measured at every protocol -specified study visit. The study manual should be referenced for collection, 
processing, and shippi[INVESTIGATOR_22026]. 
 
8.2.8.  12-Lead  ECG  
A 12 -lead ECG will be obtained at screening, Week 4 (Visit 3), Week 52 (Visit 7/ET), and 
4-week Follow -up (Visit 8). ECGs will be read locally at investigatio nal sites and interpreted for 
clinical significance. The findings will be captured in source documents and within the eCRF. 
Protocol Number PTC1240- GD-030-DMD  28 January 2016  
Version 2.0   
PTC Therapeutics, Inc. -  Confidential  
Page 30 of 63   
8.2.9.  Timed Function Tests  
Timed function tests will include the time taken to run/walk 10 meters, time to climb 4 stairs, 
time to descend 4 stairs, and time to stand up from a supi[INVESTIGATOR_2547] [ Mendell 1989, Griggs  
1991, Beenakker 2005a, Pradhan 2006] (see Study Manual for detailed instructi ons). These 
parameters will be assessed prior to ataluren dosing on the first day of treatment (Visit 2), Week 28 (Visit 5), and Week 52 (Visit 7/ET). 
 
8.2.10.  North Star Ambulatory Assessment  
The NSAA will be used to evaluate physical function, using standardized procedures (see Study 
Manual for detailed instructions). The NSAA will be performed prior to ataluren dosing on the first day of treatment (Visit 2), Week 28 (Visit 5), and Week 52 (Visit 7/ET). 
 
8.2.11.  Pharmacokinetic Assessment  
During PK assessment on Days 1 a nd 28, patients will remain in the clinic until all blood 
draws are complete. On Days 1 and 28, blood samples for PK assessment will be drawn pre -
dose and 1 (±15 min), 2 (±15 min), 4 (±30 min), 6 (±30 min), 8 (±30 min), and 10 (±30 min) hours post - dose. T hese samples will be sent to a central bioanalytical laboratory for analysis 
of ataluren levels. Please refer to the study manual for instructions regarding the collection, processing and shipment of all PK samples to the bioanalytical  laboratory.  
 
8.2.12.  Palatability Questionnaire  
The palatability questionnaire assessing characteristics of the study drug such as smell and taste will be administered at Week 4 (Visit 3). A parent/caregiver may respond on the patient’s behalf after discussing each item with the patient, age permitting. 
 
8.2.13.  Ataluren  Administration  
Refer to Sectio n 6.2. The clinic staff will administer the first dose of the study drug at Day 1 
(Visit 2).  
 
8.2.14.  Adverse Events  
Systemic AEs must be assessed and documented at each scheduled clinic visit, beginning at  
Day 1. Additional tests and other evaluations required to establish the significance or etiology of an abnormal result, or to monitor the course of an AE should be obtained when clinically indicated. Patients must be followed for AEs for at least [ADDRESS_386714] dose of ataluren administration, or until any drug- related AEs and/or ongoing SAEs have resolved or become 
stable, whichever is later.  
 
8.2.15.  Concomitant  Medications  
Concomitant medication information will be collected and documented at each scheduled clinic visit, beginning at Screening. Any concomitant drugs (prescribed or over -the-counter) used 
during the course of the study and the reason for their use will be recorded. Information regar ding the timing, type, and amount will be recorded in the eCRF.  
Protocol Number PTC1240- GD-030-DMD  28 January 2016  
Version 2.0   
PTC Therapeutics, Inc. -  Confidential  
Page 31 of 63   
8.3. Blood Collection  Summary  
Assuming a patient completes the study, the maximum amount of blood to be drawn at a visit is 
approximately 12 mL at screening, 24 mL during the 2 PK assessments, and 5 mL during the remaining visits. The total amount of blood to be drawn over the entire study (including the screening visit, treatment period, and post -treatment follow -up period) is approximately [ADDRESS_386715] medical occurrence associated with the use of a drug (investigational 
medicinal product) in humans, whether or not it is considered related to the drug. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease in a study patient who is administered study drug in this study.  
For this protocol, untoward medical occurrences that should be reported as AEs include the 
following:  
• All AEs that are suspected or are not suspected to be due to study drug 
• Overdose (administration of a study drug dose >4 times the intended total daily dose level 
for this protocol [>160 mg/kg/day]) of study drug 
• All reactions from medication misuse, abuse, withdrawal, sensitivity, or  toxicity  
• All reactions that result from medication errors or uses of the study drug outside what is described in the protocol  
• Apparently unrelated illnesses, including the worsening of a preexisting illness  
• Injury or acci dents. Note that if a medical condition is known to have caused the injury or 
accident (a fall secondary to dizziness), the medical condition (dizziness) and the accident (fall) should be reported as 2 separate AEs. The outcome of the accident (hip fractur e 
secondary to the fall) should be recorded in source  documents.  
• Abnormalities in physiological testing or physical examination findings that require clinical intervention or further investigation (beyond ordering a repeat [confirmatory]  test)  
• Laboratory a bnormalities that require clinical intervention or further investigation (beyond 
ordering a repeat [confirmatory] test) unless they are associated with an already reported clinical event. Laboratory abnormalities associated with a clinical event (eg, elevated liver enzymes in a patient with jaundice) should be captured in the source documents. Laboratory abnormalities not requiring clinical intervention or further investigation will be captured as part of overall laboratory monitoring, and should not be rep orted as  AEs.  
• A pre -existing condition (eg, allergic rhinitis) must be noted on the appropriate eCRF for 
Visit 1, but should not be reported as an AE unless the condition worsens or epi[INVESTIGATOR_245926]. Diagnostic and therapeutic  
non-invasive and invasive procedures, such as surgery, should not be reported as AEs. 
However, the medical condition for which the procedure was performed should be reported if it meets the definition of an AE. For example, an ac ute appendicitis that begins 
during the AE reporting period should be reported as the AE and the resulting appendectomy should be recorded in the source documents. If a surgical procedure was planned prior to entry into the study, and the surgery is not pe rformed because of a 
worsening of a baseline condition, this should not be reported as an AE. Note that, as 
Protocol Number PTC1240- GD-030-DMD  28 January 2016  
Version 2.0   
PTC Therapeutics, Inc. -  Confidential  
Page 33 of 63  described in Section 9.1.2, any  inpatient  hospi[INVESTIGATOR_314185].  
Each AE is to be classified as serious or non -serious by [CONTACT_314218].  
 
9.1.2.  Serious Adverse Events  (SAEs) 
An SAE is an untoward medical occurrence or effect associated with the use of a study drug at any 
dose, regardless of whether it is considered to be related to the study drug, which results in one of 
the following:  
• Death (ie, all deaths on treatment or within [ADDRESS_386716] study drug administration) , 
including deaths due to disease progression. Any death occurring later than [ADDRESS_386717] dose need not be reported as an SAE unless it is a result of an event that started within the period covered by [CONTACT_21639]- study definition. The reported AE should be 
the event that  caused the death. In addition, any AE resulting in death that occurs 
subsequent to the AE -reporting period and that the Investigator assesses as possibly 
related to the study drug should also be reported as  serious. 
• Life-threatening AE. This is an event t hat, in the view of either the Investigator or the 
sponsor, places the patient at immediate risk of death. It does not include an event that, had it occurred in a more severe form, hypothetically might have caused death. 
• Inpatient hospi[INVESTIGATOR_1081] (eg, excluding hospi[INVESTIGATOR_314186], procedures required by [CONTACT_4690], or dystrophinopathy- related diagnostic procedures; other planned 
hospi[INVESTIGATOR_602]; or hospi[INVESTIGATOR_314187]).  Treatments in the emergency room for procedures such as hydration that do not require admitting the patient to the hospi[INVESTIGATOR_314188] 24 hours are not considered ser ious. 
• Persistent or significant disability or incapacity or substantial disruption of the ability to conduct normal life functions, not related to dystrophinopathy. 
• Any other medically important event that the Investigator or the sponsor judges to be serio us or which is defined as serious by [CONTACT_314219]. 
Medical judgment should be exercised in deciding whether a reaction is serious in other situations. Important medical events that do not result in death, are not immediately l ife-
threatening, and do not require hospi[INVESTIGATOR_708], based on 
appropriate medical judgment, they may jeopardize the patient and may require medical or surgical intervention to prevent any of the outcomes listed above. Example s of such 
medical events include allergic bronchospasm requiring intensive treatment administration in an emergency room or at home, newly diagnosed malignancy, or blood dyscrasias, or convulsions that do not result in inpatient hospi[INVESTIGATOR_059], or the development of drug dependency or drug abuse.  
• An event need not be reported as a SAE if it exclusively represents a relapse or an expected change or progression of the baseline dystrophinopathy. This type of event need only to be reported as an  AE. 
Protocol Number PTC1240- GD-030-DMD  28 January 2016  
Version 2.0   
PTC Therapeutics, Inc. -  Confidential  
Page 34 of 63   
Note that any SAEs occurring after the end of the patient’s participation in the study should 
be reported to the sponsor if the Investigator becomes aware of them.  
 
9.1.3.  Unexpected Adverse Events  
Unexpected AEs are defined as those events that were not previous ly reported with study drug as 
referenced in the most current Investigator Brochure, or that are symptomatically and pathophysiologically related to a known toxicity but differ because of greater severity or specificity. For example, under this definition, hepatic necrosis would be unexpected (by [CONTACT_14213]) if the Ataluren IB only referred to elevated hepatic enzymes or hepatitis.  
Similarly, cerebral thromboembolism and cerebral vasculitis would be unexpected (by [CONTACT_14214]) if the IB only listed cerebral vascular accidents. “Unexpected,” as used in this 
definition, also refers to an AE that is mentioned in the most current IB as occurring with the 
class of drugs or as anticipated from the pharmacological properties of the study drug, but is not specifically mentioned as occurring with the medicinal  product. 
For the purposes of considering expectedness, the Ataluren IB provides a summary of the safety profile of ataluren based on available clinical information (also referred to as the reference safety information). 
9.2. Eliciting Adverse Event  Information  
The Investigator is to report all directly observed AEs and all AEs spontaneously reported by [CONTACT_314220]/guardian in case of a child. In addition, each study patient will be 
questioned about AEs at each scheduled clinic visit after study drug administration or during any 
telephone contact [CONTACT_314221]/guardian in case of a child. The type of question asked should be open -ended, eg, “ How has your child been feeling?” or a similar type of query.  
 
9.3. Adverse Event  Recording  
All AEs (both serious and non- serious) that occur in patients during the AE reporting period 
must be recorded, whether or not the event is considered dr ug related. In addition, any known 
untoward event that occurs subsequent to the AE reporting period that the Investigator assesses as possibly related to the investigational drug/product should also be recorded as an AE.  
All AEs are to be recorded in the s ource documents and on the eCRF using concise medical 
terminology; whenever possible terms contained in Medical Dictionary for Regulatory Activities 
(MedDRA) should be employed. In addition, the following information should be recorded:  
• Indication of wheth er the event is serious or non- serious (see Section  9.1.2)  
• Relationship to study drug (see Section  9.4) 
• Severity of the event (see Section  9.5) 
• Onset date  
• Resolution date, or date of  death  
• Action  taken  
• Outcome of the  event  
Protocol Number PTC1240- GD-030-DMD  28 January 2016  
Version 2.0   
PTC Therapeutics, Inc. -  Confidential  
Page 35 of 63   
Classification of the event as serious or non- serious determines the reporting procedures to be 
followed. 
 
9.4. Describing Adverse Event Relationship to Study  Drug  
Based on the considerations outlined in Table 3 the Investigator should provide an assessment of 
the relationship of the AE to the study drug, ie, whether there is a reasonable possibility that the 
study drug caused the AE. 
Table 3:  Relationship of Study Drug to Adverse Event  
 
Relationship  Description  
Probable  A clinical event in which a relationship to the study drug seems probable because of such factors as 
consistency with known effects of the drug; a clear temporal association with the use of the drug; 
improvement upon withdrawal of the drug; recurrence upon rechallenge with the drug; lack of 
alternative explanations for the event.  
Possible  A clinical event occurring coincident with administration of the study drug and which may or may not 
be explained by [CONTACT_9153]. Information on drug withdrawal or 
rechallenge may be lacking.  
Unlikely  A clinical event with a temporal relationship to the study drug exposure that does not preclude causality 
but for which the re is a clear alternate cause that is more likely to have caused the AE than study drug. 
Such alternatives include a concomitantly administered drug, the patient’s disease state, other medical 
conditions, or environmental factors.  
Unrelated  A clinical event, for which a relationship to the study drug seems improbable because of factors such as 
inconsistency with known effects of the study drug, lack of a temporal association with study drug 
administration, lack of association of the event with study drug withdrawal or rechallenge, and/or 
presence of alternative explanations for the event. Alternative explanations might include a known 
relationship of the AE to a concomitant drug, medical history of a similar event, the patient’s disease 
state, o ther medical conditions, or environmental factors.  
 
9.5. Grading of Severity of Adverse  Events  
The severity of AEs will be graded using CTCAE v 4.0 (refer to the study manual). For each 
epi[INVESTIGATOR_1865], the highest severity grade attained should be reported.  
If a CTCAE criterion does not exist, the Investigator should use the grade or adjectives: Grade 1 
(mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (life -threatening), or Grade 5 (fatal) to 
describe the maximum intensity of the AE. For purposes of cons istency with the CTCAE, these 
intensity grades are defined in Table 4 . 
Protocol Number PTC1240- GD-030-DMD  28 January 2016  
Version 2.0   
PTC Therapeutics, Inc. -  Confidential  
Page 36 of 63   
Table 4:  Grading of Adverse Event  Severity  
 
Grade  Adjective  Description  
Grade [ADDRESS_386718] on the patient’s overall health and well- being, does not 
interfere with the subject’s usual function, and is not likely to require medical 
attention  
Grade 2  Moderate  Sign or symptom causes interference with usual activity or affects clinical status, 
and may require medical intervention  
Grade 3  Severe  Sign or symptom is incapacitating or significantly affects clinical status and 
likely requires medical intervention and/or close follow up  
Grade 4  Life-threatening  Sign or symptom results in a potential threat to life  
Grade 5  Fatal  Sign or symptom results in death  
 
Note the distinction between the seriousness and the severity of an AE. Severity is a measure of 
intensity; thus, a severe reaction is not necessarily a serious reaction. For example, a headache may be severe in intensity but would not be classified as ser ious unless it met one of the criteria 
for serious events listed in Section 9.1.2. 
 
9.6. Follow -Up of Unresolved Adverse Events  
All AEs should be followed up by [CONTACT_314222], or the Investigator 
assesses them as chronic or stable. Follow -up of any SAE that is fatal or life -threatening should 
be provided within one additional calendar week. The Investigator should consider protocol guidelines and use his/her discretion in ordering addi tional tests as necessary to monitor the 
resolution of such events. In the event of additional investigations, the PTC Therapeutics Safety Department or designee should be informed via e -mail or fax. A patient withdrawn from the 
study because of an AE must  be followed by [CONTACT_314223], or until progression has been stabilized.  Follow -up may need to continue after the patient has discontinued from the study, and additional  
investigations may be requested by [CONTACT_314224]. 
 
9.7. Adverse Event Reporting  Period  
The first day of AE reporting will coincide with the day the first dose of study drug is administered. The AE reporting period for this study ends with the 4- week post -treatment 
follow -up visit, except as described in Section 9.3. In addition, SAEs occurring in a patient after 
the study period should be reported to the sponsor if the Investigator becomes aware of them.  
 
9.8. Investigator Site Adverse Event Reporting  Requirements  
Classification of an event as serious or non -serious (see Section 9.1.2) determines the reporting 
procedures to be followed. Investigator site reporting requirements for AEs are summarized in 
Table 5 . 
Protocol Number PTC1240- GD-030-DMD  28 January 2016  
Version 2.0   
PTC Therapeutics, Inc. -  Confidential  
Page 37 of 63   
Table 5:  Investigational Site Requir ements for Reporting Adverse Events  
 
Classification  Reporting Time  Reporting 
Action  
 
 
 
Serious  Within 24 hours  E-mail, fax or telephone call to the PTC Therapeutics 
Safety Department/designee within 24 hours.  
 
Within 5 calendar days  Provide photocopi[INVESTIGATOR_314189] (eg, progress notes, nurses’ notes, laboratory and 
diagnostic test results, discharge summaries) as requested by 
[CONTACT_314225]/designee.  
Per CRF submission procedure  Record and submit information on appropriate CRFs  
(eg, Medical History and Concomitant Medications CRFs)  
 
 
 
AESI  Within 24 hours  E-mail, fax or telephone call to the PTC Therapeutics Safety  
Department/designee within 24 hours.  
 
Within 5 calendar days  Provide photocopi[INVESTIGATOR_314190] (eg, 
progress notes, nurses’ notes, laboratory and diagnostic test 
results,  
discharge summaries) as requested by [CONTACT_314226]/designee.  
Per CRF submission procedure  Record and submit information on appropriate CRFs  
(eg, Medical History and Concomitant Medications CRFs)  
 
Nonserious   
Per CRF submission procedure  Record and submit information on appropriate CRFs  
(eg, Adverse Events, Medical History and 
Concomitant Medications CRFs)  
a Patient name, address, and other personal identifiers should be  obscured.  
Abbreviations : AESI = AEs of special interest, eCRF = electronic case report form, IRB/IEC = Institutional Review 
Board/Independent Ethics Committee, SAE = Serious Adverse Event  
 
For SAEs, in addition to completing the AE eCRF, the SAE report form must also be completed. 
The SAE report form should be signed by [CONTACT_737]; however, if the Investigator is unable to sign at the time of the  event or within 24 hours, the form should be signed by [CONTACT_314227] (eg, the study coordinator). The SAE report form must be faxed or emailed to the PTC Therapeutics Safety Department or designee and to the site IRB/IEC (if required by [CONTACT_427]) within 24 hours. Follow -up information to the SAE should be 
clearly documented as “follow up” in the SAE report form and must also be faxed or emailed to the same parties. All follow up SAE report forms for the event must be signed by [CONTACT_737]. Any source documents (eg, progress notes, nurses’ notes, laboratory and diagnostic test results, discharge summaries) provided to the sponsor must be redacted so that the patient’s 
name, address, and other personal identifiers a re obscured. Only the patient’s study number and 
initials are to be provided (in regions where the provision of such information is permitted). The 
information in the AE eCRF and the SAE report form(s) must match or be reconciled.  Where the same data are collected, the forms must be completed in a consistent manner. For example, 
the same AE term should be used on both forms.  
In the rare event that the Investigator does not become aware of the occurrence of an SAE immediately (for example, if a patient initially seeks treatment elsewhere), the Investigator is to document his/her first awareness of the AE and report the event within 24 hours after learning of it. 
The PTC Therapeutics Safety Department/designee contact [CONTACT_314228] d below. This information is also provided in the Investigator File and the back- up paper 
SAE report form.  
Protocol Number PTC1240- GD-030- DMD  28 January 2016  
Version 2.0  
PTC Therapeutics, Inc. - Confidential 
Page 38 of 63   
PTC Therapeutics Safety Department  
Attention:   
Telephone  
Facsimile:  
E-mail:   
 
9.9. PTC Therapeutics Adverse Event Reporting  Requirements  
As the sponsor of the study, PTC Therapeutics is responsible for reporting certain safety 
information, particularly SAEs and patient deaths related to participation in the study, to each Investigator in an expedited manner. If notification of an AE requiring expedited reporting to investigators is received, PTC Therapeutics or its designated representative will contact [CONTACT_314229] e -mail, fax, and/or overnight mail such that the 
Investigator can promptly notify the site IRB/IEC per their local requirements. The initial expedited safety report will be provided as required according to local regulations (eg, within 15 days) after the earliest date PTC Therapeutics or an agent of PTC Therapeutics (eg, a site monitor) becomes aware of an AE. This awareness date is the date the regulatory reporting clock begins and the date is considered Day 0. 

Protocol Number PTC1240- GD-030-DMD  28 January 2016  
Version 2.0   
PTC Therapeutics, Inc. -  Confidential  
Page 39 of 63   
10. WITHDRAWAL OF  SUBJECTS  
All patients who receive ataluren should remain in the study whenever possible. However:  
• The parent/caregiver has the right to withdraw consent and discontinue ataluren at any 
time.  
• If the patient’s condition substantially worsens after initiating ataluren, the patient will be carefully evaluated by [CONTACT_737]. The patient 
will be withdrawn from treatment if continuing would place them at  
risk. 
• The Investigator may withdraw the patient  from ataluren, if, in the 
Investigator’s clinical judgment, it is not in the patient’s best interest to continue. 
• In the event that the patient becomes significantly noncompliant with ataluren administration, study procedures, or study requirements, the patient should be withdrawn from ataluren when the circumstances surrounding noncompliance increase risk to the patient or are anticipated to substantially compromise the interpretation of study results.  
• This study may be discontinued by [CONTACT_314230], IRB/EC, and/or PTC Therapeutics at any time.  
The date ataluren is discontinued and the reason for discontinuation will be recorded in the 
source documents and in the eCRF. The PTC medical monitor (or designee) should be infor med 
via e- mail of when a patient discontinues study drug. 
When ataluren is discontinued (regardless of the reason), the Investigator is expected to capture 
all of the evaluations required at the end of treatment or Follow -up and any additional 
evaluations should be completed that may be necessary to ensure that the patient is free of 
untoward effects. The patient should be encouraged to seek appropriate follow -up for any 
continuing health problems. 
Protocol Number PTC1240- GD-030-DMD  [ADDRESS_386719] e size of 12 patients for this study is not based on formal statistical considerations. 
However, preliminary results from population PK (popPK) simulation indicate that the current 
study design (sample size and sparse sampling strategy) will provide adequa te precision for the 
prediction of PK parameters (apparent clearance and volume of distribution) even considering the usual potential for subject dropouts and/or missing samples [ Wang 2012, FD A General  
Clinical Pharmacology Considerations for Pediatric Studies for Drugs and Biological Products  
2014].  
 
11.2. Analysis  Populations  
All patients who receive at least [ADDRESS_386720] listings will be created for each eCRF module. Summary tables for continuous 
variables will contain the following statistics: N, mean, median, standard deviation, standard error, minimum, maximum, and 95% confidence intervals (CIs) as appropriate. Summary tables for categorical variables will include N and percentage. Graphical techniques will be used when such methods are appropriate and informative.  
Transformations of the data may be explored if warranted by [CONTACT_314231].  
All analyses will be performed using Statistical Analysis System (SAS® Version 9.0 or higher).  
The primary analysis will be conducted on data obtained during the 4- week PK period of the 
study and may be reported separately from the extension study data. 
 
11.4. Subject Disposition and Baseline  Characteristics  
The numbers of patients screened and enrolled will be summarized. Reasons for screen failures will be presented. The number of patients receiving ataluren will be described. Patients who do not complete the planned observations will be described and evaluated separately. Patients receiving ataluren who are found not to have fully met the eligibility criteria will be described. On-study protocol violations will also be presente d. Reasons for study discontinuation and dates 
of withdrawal from study will be described.  
Patient characteristics at baseline will be summarized using appropriate descriptive statistics.  
 
11.5. Efficacy Endpoints  
Observed values and changes from baseline in tim ed function tests, NSAA total score and 
composite score will be summarized descriptively.  
Protocol Number PTC1240- GD-030-DMD  28 January 2016  
Version 2.0   
PTC Therapeutics, Inc. -  Confidential  
Page 41 of 63   
11.6. Pharmacokinetic Parameters  
PK parameters of ataluren on Day 1 and 28 will be derived using non- compartmental analysis 
(NCA) methods. The PK parameters of at aluren listed below will be derived following the 
morning dose on Day [ADDRESS_386721] quantifiable 
concentration (C trough) using the linear trapezoidal rule during the ascending portion of the curve 
and the log- trapezoidal rule during the descending portion of the curve  
 
AUC 0-10 Area under the plasma concentration time curve from time zero up to 10 hours after the morning dosing using the linear trapezoidal rule during the ascending portion of the curve and the log-  
trapezoidal rule during the descending portion of the curve  
Cmax Maximum observed plasma concentration  
Ctrough@6h  Concentration at the end of the first (morning) dosage interval  
tmax Time of maximum observed plasma concentration  
λz Terminal rate constant  
t1/[ADDRESS_386722](2) / λ Z 
 
 
The accumulation ratio on Day 28 will be calculated as follows:  
 
Parameter  Description  
AR(AUC)  AR(AUC) = (AUC 0-t)Day28 / (AUC 0-t) Day  1 
AR(C max) AR(C max) = (C max) Day28 / (C max)Day  1 
 
Individual PK parameters will be derived using actual sampling and dosing times. 
Concentrations below the limit of quantitation (LOQ) will be set to zero for the calculation of NCA parameters. PK parameters will be summarized with descriptive statistics on Day 1 and 28 (eg, n, arithmetic mean, standard deviation, standard error, median, minimum, and maximum, CV% mean, geometric mean, and CV% geo metric mean). The analysis will be performed with a 
fully validated version of Phoenix WinNonlin V6.3. 
In addition, a popPK analysis will be performed by [CONTACT_314232] 1 and 28 in order to explore the potential time -dependency of ataluren and derive the 
following additional PK parameters.  
Protocol Number PTC1240- GD-030-DMD  28 January 2016  
Version 2.0   
PTC Therapeutics, Inc. -  Confidential  
Page 42 of 63   
Parameter  Description  
ka Rate constant of absorption  
CL/F  Apparent clearance  
CLd/F  Apparent distribution clearance  
Vc/F  Apparent volume of distribution  
   
Vp/F  Apparent peripheral volume of distribution  
 
The above PopPK model will be used to simulate rich concentration- time profiles and derive the 
area under the curve over 24 hours (AUC 0-24). 
A two -compartment model with time -dependent clearance (between the morning and midday 
dose), was previously used to assess the concentration- time profiles of ataluren in adult patients 
with nonsense -mutation Duchenne -Becker muscular dystrophy. If required, data collected in the 
current study (≥2 to <5 year ol d nmDMD patients) may be merged with data collected in adult 
patients with nmDMD to assess potential effect of age and/or body weight on PK parameters of 
ataluren.  
Additional information will be provided in the PK analysis plan. 
 
11.7. Safety  
 
11.7.1.  Adverse Events  
Adverse events will be tabulated by [CONTACT_314233]. The severity of the 
AE will be graded using the CTCAE whenever possible. For AEs that are not included in the CTCAE, the grading categories (mild, moderate, severe, life -threatening, and fatal) described in 
Table 4  will be used. The frequency of patients experiencing a specific AE will be tabulated by 
[CONTACT_9313]; preferred term; seriousness (serious vs nonserious; see Section 9.1.2) ; timing 
of occurrence, outcome, and relationship to study drug (see Section 9.4) ; and worst severity (see 
Section 9.5) In the by- subject analysis, a patient h aving the same event more than once will be 
counted only once and will be classified at the highest severity and/or relatedness for those events.  
Adverse events classified as CTCAE Grade ≥3; study- drug- related events; hepatic, and renal 
events leading to special diagnostic evaluations; events leading to discontinuation of ataluren, events leading to death, and SAEs will be considered with special attention.  
 
11.7.2.  Laboratory Parameters  
Hematological and biochemistry data will be summarized by [CONTACT_82065] d will be graded according 
to CTCAE severity grade, when applicable. The frequencies of the worst severity grade observed 
will be displayed. For variables graded according to CTCAE severity grade, the frequencies of 
Protocol Number PTC1240- GD-030-DMD  [ADDRESS_386723] severity grade observed. 
 
11.7.3.  Vital Signs and  ECGs  
Vital signs (height, weight, BMI, pulse rate, and body temperature) and ECGs will be listed and 
summarized by [CONTACT_765]. Where appropriate, changes from baseline will be pres ented by [CONTACT_765]. 
 
11.7.4.  Other Safety  Parameters  
Physical examination data will be described. Where appropriate, changes from baseline will be 
presented by [CONTACT_765]. 
 
11.7.5.  Interim Safety  Review  
An interim safety analysis is planned with the assistance of the DMC; the analysis will be a 
safety review when all patients have completed ≥ [ADDRESS_386724] additional safety reviews for specific 
patients or all patients.  
 
11.8. Treatment Administration a nd Drug  Compliance  
Study drug compliance will be assessed by [CONTACT_314234]. Compliance will be analyzed as a percentage of drug actually taken relative to the amount that was specified to be taken during the study.  
 
11.9. Use of Concomitant Medication and Supportive  Therapy  
Concomitant medications will be coded by [CONTACT_314235] (WHODRUG) into Anatomical -Therapeutic- Chemical (ATC) classification codes. 
The type and timing of use of specific concomitant medications will be listed and summarized.  
The frequency, timing, type, and amount of any other therapi[INVESTIGATOR_314191].  
 
11.10.  Palatability Questionnaire  
Palatability data will be summarized descriptiv ely. 
 
11.11.  Exploration of  Correlations  
Correlations between patient characteristics and outcome measures, and correlations among 
outcomes measures may be explored using regression models or other appropriate techniques.  
Protocol Number PTC1240- GD-030-DMD  [ADDRESS_386725] impartial, independent decision -making. Specialists may be invited to participate as non- voting members at any time if 
additional expertise is desired. 
Protocol Number PTC1240- GD-030-DMD  28 January 2016  
Version 2.0   
PTC Therapeutics, Inc. -  Confidential  
Page 45 of 63   
13. OBLIGATIONS OF THE INVESTIGATOR AND THE  SPONSOR  
 
13.1. Compliance with Ethical and Regulatory Guidelines  
The Investigator is responsible for ensuring that the clinical study is performed in accordance 
with the International Council on Harmonisation (ICH) GCP guidance documents and the Declaration of Helsinki.  
13.2. Institutional Review Board/Independent Ethics  Committee  
Prior to enrollment of patients into the study, as required by [CONTACT_12721], the protocol 
and informed consent doc ument will be reviewed and approved by [CONTACT_4215]/IEC. By 
[CONTACT_12142], the Investigator assures that approval of the protocol will be obtained from the IRB/IEC and that all aspects of the IRB/IEC review will be conducted in accordance with  
current regulations. Amendments to the protocol will be subject to the same IRB/IEC review requirements as the original protocol. Only changes necessary to eliminate apparent immediate hazards to the patients may be initiated prior to IRB/IEC approval. In that event, the Investigator must notify the IRB/IEC and PTC Therapeutics in writing within 5 working days after implementation. The Investigator will also promptly notify the IRB/IEC of any serious, unexpected AEs or any other information that may affect  the safe use of the drug during the 
course of the study.  
A letter documenting the IRB/IEC approval and a list of the names and titles of the IRB/IEC 
members must be received by [CONTACT_314236]. All 
correspondence with  the IRB/IEC should be retained in the Investigator’s study file. 
The Investigator shall submit a progress report, at least once yearly, to the IRB/IEC, and must provide a copy to PTC Therapeutics. As soon as possible after completion or termination of the  
study, the Investigator will submit a final report to the IRB/IEC and to PTC Therapeutics. This report should include the dates of initiation and completion of the study, a description of any 
changes in study procedures or amendments to the protocol, any deviations from the protocol, the number and type of patients evaluated, the number of patients who discontinued (and the reasons for discontinuation), the number of patients who completed the study, and the results of the study, including a description of  any AEs. PTC Therapeutics will assist the Investigator in 
the preparation of this report, as needed.  
 
13.3. Informed  Consent/Assent  
By [CONTACT_12142], the Investigator assures that informed consent/assent will be obtained from each patient and/or parent/l egal guardian prior to study entry and that the informed 
consent/assent will be obtained in accordance with current regulations.  
The Investigator or sub -investigator will give each patient and/or parent/guardian full and 
adequate verbal and written informa tion regarding the objectives and procedures of the study and 
the possible risks involved. An informed consent/assent document will be provided to each patient and/or parent/guardian in a language in which the patient or parent/guardian is fluent.  
This inf ormation must be provided to the patient or parent/guardian prior to undertaking any 
study- related procedure. Adequate time should be provided for the patient and/or  
Protocol Number PTC1240- GD-030-DMD  28 January 2016  
Version 2.0   
PTC Therapeutics, Inc. -  Confidential  
Page 46 of 63   
parent/guardian to read the informed consent, to understand the risks and benefits of participating 
in the study, and to ask any questions that the patient and/or parent/guardian may have about the study. The patient and/or parent/guardian should be able to ask additional questions as and when needed during the conduct of the st udy. The patient’s and/or parent(s)/guardian signature (as 
required by [CONTACT_427]) on the informed consent form should be obtained at the investigational site in the presence of the Investigator or a qualified representative  
(eg, sub- investigator). Where applicable, the patient will sign an age -appropriate assent form.  
Each patient or parent/guardian will be given a copy of the signed consent/assent form. The original signed informed consent forms will be retained by [CONTACT_314237].  
The written patient information must not be changed without prior approval by [CONTACT_314238]/IEC.  
 
13.4. Case Report  Forms  
An eCRF is required and must be completed for each patient, with all required study data accurately recorded such that the information matches the data contained in medical records (eg, physicians’ notes, nurses’ notes, clinic charts, and other study- specific source documents).  
The eCRFs exist within a Web -based EDC system managed by [CONTACT_314239] y. After the Investigator or the Investigator’s designees (eg, research coordinators) have 
been appropriately trained, they will be given access to the EDC system and will enter the data 
required by [CONTACT_314240]. Any change of data will  be made via the EDC 
system, with all changes tracked by [CONTACT_314241].  
With an electronic signature, the Investigator certifies that the data are complete and accurate 
prior to database lock. This electronic signature [CONTACT_314255]. After database lock, the investigational site will receive a CD -ROM and/or 
paper copi[INVESTIGATOR_314192]. At all times, the principal 
Investigator [INVESTIGATOR_314193] l responsibility for the accuracy and authenticity of all clinical data entered 
onto the eCRFs and/or reported to PTC Therapeutics from the investigational  site. 
 
13.5. Study  Records  
During the study, the Investigator will maintain adequate records for the study, including medical records, source document records detailing the progress of the study for each patient, laboratory reports, a CD -ROM or paper copy of the data that have been captured in the EDC for 
each patient (electronic equivalents of CRFs), pap er CRFs, signed informed consent forms, 
ataluren reconciliation and dispensing records, correspondence with the IRB/IEC, AE reports, and information regarding patient discontinuation and completion of the study. Current regulations require PTC Therapeutics  (or an authorized designee) to inspect all documents and 
records required to be maintained by [CONTACT_737], including but not limited to medical records (office, clinic, or hospi[INVESTIGATOR_307]) for the patients enrolled in this study. These regulations also allow the same records to be inspected by [CONTACT_314242], Health  Canada, 
or other regulatory authorities.  
Protocol Number PTC1240- GD-030-DMD  [ADDRESS_386726] 
confidence and will not appear on eCRFs, paper CRFs, or other records provided to or retained by [CONTACT_314216] (or its authorized designee). The names and identities of the patients need 
not be divulged; however, the records must nevertheless be inspected. This will be accomplished by [CONTACT_314243]’s name [CONTACT_233591]’s study identification number on any record provided to or retained by [CONTACT_314216]. The informed consent form must include appropriate statements explaining these requirements. 
By [CONTACT_12570], the Investigator affirms to PTC Therapeutics that the Investigator will 
maintain, in conf idence, information furnished by [CONTACT_314244]/IEC under an appropriate understanding of confidentiality with such board.  
 
13.7. Retention of  Records  
To enable evaluations and/or audits from regulatory authorities or PTC Therapeutics, the Investigator agrees to keep accurate and complete records, including the identity of all participating patients (sufficient information to link eCRFs and clinic records), all original signed informed consent forms, CD -ROM or paper copi[INVESTIGATOR_314194] (electronic equivalents of CRFs), and detailed records of ataluren disposition. All records and documents pertaining to the study (including but not limited to those 
outlined in Section 13.5 above) will be maintained by [CONTACT_314245]. 
The Investigator must obtain written permission from PTC Therapeutics before disposing of any 
records. In order to avoid any possible errors, the Investigator will contact [CONTACT_314246]. The Investigator will promptly notify 
PTC Therapeutics in the event of accidental loss or d estruction of any study records. If the 
Investigator relocates, retires, or for any reason withdraws from the study, the study records may 
be transferred to an acceptable designee, such as another Investigator, another institution, or to PTC Therapeutics.  
 
13.8. Monitoring and  Auditing  
In accordance with 21 CFR Part 312.56 and/or relevant ICH guidelines, PTC Therapeutics or a designee will periodically inspect all eCRFs (see Section 13.4) , study documents, research 
facilities, and clinical laboratory facilities associated with this study at mutually convenient times, before, during, and after completion of the study. As required by [CONTACT_5279] (Responsibilities of Sponsors and Investigators), the monitoring visits provide  PTC Therapeutics 
with the opportunity to evaluate the progress of the study; verify the accuracy and completeness of data in the eCRFs; ensure that all protocol requirements, other relevant regulations, and Investigator’s obligations are being fulfilled; and resolve any inconsistencies in the study records. This includes inspection of all documents and records required to be maintained by [CONTACT_737], including but not limited to medical records (office, clinic, or hospi[INVESTIGATOR_307]) for the patients in this s tudy. The names and identities of all research subjects will be kept in strict 
Protocol Number PTC1240- GD-030-DMD  28 January 2016  
Version 2.0   
PTC Therapeutics, Inc. -  Confidential  
Page 48 of 63  confidence and will not appear on eCRFs or other records provided to or retained by  
[CONTACT_314216]. The Investigator/institution guarantees direct access to source documents by 
[CONTACT_314247]. 
The investigational site may also be subject to review by [CONTACT_1201]/IEC, to quality assurance 
audits performed by [CONTACT_314248] a designee, and/or to inspection by [CONTACT_3527]. The G CP regulations also require the Investigator to allow authorized representatives 
of the regulatory authorities to inspect and make copi[INVESTIGATOR_314195]. 
It is important that the Investigator and relevant institutional personnel are available during t he 
monitoring visits and possible audits or inspections, and that sufficient time is devoted to the 
process.  
13.9. Termination of the  Study  
PTC Therapeutics reserves the right to discontinue the study prior to inclusion of the intended 
number of subjects. The Investigator, after consultation with the PTC Therapeutics medical monitor, reserves the right to discontinue the study at the investigational site for safety reasons at any time.  
After a decision to terminate the study, investigators must co ntact all subjects who are continuing 
their participation in the study and must do so within a time period set by [CONTACT_314216]. As directed by [CONTACT_314216], all study materials must be collected and all electronic data entry forms completed to the greatest extent possible.  
 
13.10.  Public Notification of Study  Conduct  
Consistent with requirements of the International Committee of Medical Journal Editors (ICJME) as a condition of consideration for publication of study results, PTC Therapeutics will be responsible for ensuring that this protocol is listed at the ClinicalTrials.gov website.  
PTC Therapeutics will also be responsible for ensuring that information at this website relating 
to study design and conduct is appropriately updated during the course of the study. In order to 
facilitate this process, investigators will need to supply PTC Therapeutics with appropriate 
contact [CONTACT_314249].  
 
13.11.  Dissemination of  Results  
The information developed during the conduct of this clinical study is considered confidential by 
[CONTACT_314216]. This information may be disclosed as deemed necessary by 
[CONTACT_314216].  
To allow for the use of the information derived from this clinical study and to ensure compliance with current regulat ions, the Investigator is obliged to provide PTC Therapeutics with complete 
test results and all data developed in this study. The information obtained during this study may be made available by [CONTACT_314250], Health Canada, or other regulatory authorities. Such information may be disclosed as deemed necessary by [CONTACT_314216].  
PTC Therapeutics intends for the data from this study to be presented and published. The PTC Therapeutics staff under the direction of the PTC Therapeutics chief medical officer in  
collaboration with the Investigator will be responsible for writing presentations and manuscripts  
Protocol Number PTC1240- GD-030-DMD  28 January 2016  
Version 2.0   
PTC Therapeutics, Inc. -  Confidential  
Page 49 of 63   
for publication. Investigators will not be allowed to publish or present the data from this study 
without prior agreement with PTC Therapeutics.  
 
13.12.  Communication with Regulatory Authorities  
PTC Therapeutics will assume responsibility for regulatory interactions with the FDA, Health Canada, and/or other regulatory authorities. In fulfilling this responsibility, PTC Therapeutics (or a designee) will collect, assemble, and communicate all required regulatory documents (eg, Investigator financial disclosure forms, protocol and protocol amendments, investigator brochure s, informed consent documents, annual reports) as required by [CONTACT_5151]. 
PTC Therapeutics (or a designee) will also assume responsibility for AE reporting to regulatory authorities as described in Section 9.9. 
Protocol Number PTC1240- GD-030-DMD  [ADDRESS_386727]  Selection  
 
14.1.1.  General  
This study is an open- label PK, efficacy, and safety study of ataluren in subjects with nmDMD. 
Consistent with GCP guidelines, parents/guardians and subjects must provide informed 
consent/assent b efore initiation of any study procedures. To minimize missing data and 
premature discontinuations, subjects must have the personal and family resources to comply with study procedures and restrictions. In addition, subjects must not have serious concomitant conditions that would compromise safety, compliance, or evaluation.  
 
14.1.2.  Inclusion of  Minors  
Inclusion of children ≥2 to <5 years old in this protocol is appropriate and necessary. The benefit -risk ratio is enhanced by [CONTACT_314251], the generally favorable safety profile of ataluren, and the limited population of patients with nonsense -mutation -mediated disease (~13% 
of the total dystrophinopathy populat ion). Inclusion of young children will allow an 
understanding of how age -dependent disease characteristics may affect PK parameters and, 
therefore, dosing.  
In standard toxicology studies, dosing is initiated in young adult rats (6 to 8 weeks old) and in 4 - 
to 6-month old dogs. However, the chronic toxicology studies conducted with ataluren initiated 
dosing in weanling animals (approximately 4-  to 5- week -old rats, and dogs <3 months  
of age) to support dosing of pediatric subjects as young as 2 years of age. A detailed summary of 
methods and results of these chronic toxicity studies is provided in Section 7 of the Ataluren IB.  
In the clinic, ataluren has previously been administered to patients as young as 3 years old. A Phase 2 study of ataluren in patients w ith methylmelonic acidemia (MMA) enrolled 11 patients, 
including 2 patients who were 3 years old and 1 patient who was 4 years old. All 3 of these patients completed the study as planned, receiving ataluren 5, 5, 10 mg/kg for 28 days in Cycle 1 and ataluren 10, 10, 20 mg/kg for 28 days in Cycle 2; there was a washout period of 21 days between the cycles.  
Ataluren was well tolerated by [CONTACT_941] 3 patients <6 years old in the MMA study. Treatment - 
emergent AEs in these patients were vomiting, pyrexia, nasopharyngitis, cough, flatulence, and rash. All treatment- emergent AEs were mild or moderate in severity, and none were serious or 
led to discontinuation of treatment. Overall, the ataluren safety profile was similar in patients <6 
years old and ≥6 years  old. 
Twenty -four hour blood sampling for ataluren PK assessments was performed on Day 28 of each 
cycle; the data from Cycle 2, in which a dose of 10, 10, 20 mg/kg was administered, are of particular relevance to the proposed study. Ataluren plasma concent rations in the 3 patients  
<6 years old were comparable to ataluren plasma concentrations in the 8 patients ≥6 years old who participated in the MMA study. Mean AUC
0-24h was 279.3 h•µg/mL and 358.4 h•µg/mL for 
patients <6 and ≥6 years old, respectively, on Day 28 of Cycle 2. Mean C max was 28.2 µg/mL  
Protocol Number PTC1240- GD-030-DMD  28 January 2016  
Version 2.0   
PTC Therapeutics, Inc. -  Confidential  
Page 51 of 63   
and 29.9 µg/mL for patients <6 and ≥6 years old, respectively, on Day 28 of Cycle 2 (10, 10, 20 
mg/kg). These data suggest similar ataluren PK profiles in patients <6 and ≥6 years old.  
In Phase 2 clinic al studies, ataluren has demonstrated comparable PD activity and safety, as well 
as PK profiles similar to adult patients, in children >6 years old with CF [ Clancy 2006, Kerem  
2008, Sermet -Gaudelus 2010, Wilschanski 2011]. The drug has also shown PD activity and was 
generally well -tolerated at the dose used in that study and a higher dose level in children with 
DMD [ Finkel 2013 ]. 
During study conduct, patients will be monitored closely for adverse clinical and laboratory 
events. This protocol clearly defines the actions to be taken if AEs occur. Procedures have been 
established for defining AEs, eliciting AE information, recording AEs, evaluating the 
relationship of AEs to the study drug, grading the severity of AEs, following up on unresolved AEs, and reporting AEs. These procedures are fully detailed in Section 9.  Additional risk/benefit information that becomes available during the conduct of the study will be provided to each investigational site as a “letter to the Investigator” or safety alert. In addition, pain and discomfort will be  prevented as much as possible, and investigations will be limited to a 
minimum necessary to provide meaningful data and performed using size/age appropriate material and devices.  
 
14.1.3.  Reproductive Considerations  
Ataluren is not genotoxic, did not affect fertility in male and female rats, and was not teratogenic in rats and rabbits. In addition, lack of sexual maturity in the subjects enrolled in this study limits reproductive  risks.  
 
14.1.4.  Prior and Concomitant  Therapi[INVESTIGATOR_314196]; however, efforts will be made to avoid use of concomitant medications that might confound interpretation of study results or pose a safety 
risk. Ataluren has not proved allergenic in studies performed to date, but review of known 
allergies to excipi[INVESTIGATOR_314197]. As substantial modification of corticosteroid dosing due to manifestation of undesirable side effects such as osteoporosis during the study may confound study results, investigators and subjects are encouraged to maintain corticosteroid dosing as uniformly as possible. 
In vitro studies have suggested that ataluren is potentially an inhibitor of CYP450, 2C8 and 2C9 
at concentrations that may be achieved in the clinic. Because ataluren may slow the clearanc e of 
medications that are primarily metabolized by [CONTACT_097]2C8 or CYP2C9, investigators should pay specific attention to use of drugs that are known substrates of this enzyme, particularly when such drugs may have a low therapeutic index.  
While no clinical evid ence of drug -drug interactions has been demonstrated, the potential for 
ataluren interactions with other drugs has been assessed. Based on in vitro studies, ataluren is a substrate of UGT1A9 and BCRP. The clinical drug- drug interaction study for ataluren w ith a 
strong UGT1A9 inducer (eg, rifampin) has been conducted. Although the average ataluren C
max 
and AUC were reduced posttreatment of rifampin (~11% and ~29%, respectively), these changes are considered not to be clinically important. Caution should be e xercised when ataluren is co - 
administered with drugs that are inhibitors of BCRP. 
Protocol Number PTC1240- GD-030-DMD  28 January 2016  
Version 2.0   
PTC Therapeutics, Inc. -  Confidential  
Page 52 of 63   
In vitro data indicate that ataluren is an inhibitor of UGT1A9, OAT1, OAT3 and OATP1B3. 
Caution should be exercised when ataluren is co- administered with drugs tha t are substrates of 
UGT1A9, OAT1, OAT3, or OATP1B3 because of the risk of increased concentration of these drugs. 
Physicians and subjects are encouraged to avoid the use of extraneous drugs or alternative 
therapi[INVESTIGATOR_314198]- drug interactions might occur. In 
particular, physicians are advised to closely monitor subjects when drugs of low therapeutic index that are cleared by [CONTACT_097]2C9 are administered concomitantly with ataluren.  
Specific drugs that are prohibited during the study are listed in the Exclusion Criteria (see Section 4.3) . 
 
14.2. Treatment Rationale  
 
14.2.1.  Ataluren Schedule and Dose  Selection  
Dosing based on body weight will be employed. Such dosing is common in pediatrics and 
reduces variability in exposure by [CONTACT_314252]. The preliminary results from a 
popPK simulation indicated that the current study design of 10, 10, 20 m g/kg dose in 12 patients 
with 7 -point sampling after the morning dose would provide good precision of the estimates of 
CL/F and Vd/F, according to FDA recommendation. 
The schedule of drug administration was derived directly from Phase 1 PK modeling and from 
Phase 2 exposure information. The intent of administering 2 smaller doses at 6- hour intervals 
during the day and a larger dose at a 12- hour interval overnight (eg, at 7:00 AM, 1:00 PM, and 
7:00 PM) is to optimally sustain target plasma concentrations whi le minimizing total exposures. 
This schedule is likely to fit well with daily patterns of living for patients, thus enhancing compliance. As confirmation of that premise, compliance with ataluren dosing in Phase [ADDRESS_386728] extensively at the 10, 
10, 20 mg/kg dose level. In the Phase 2b, randomized, double -blinded, placebo- controlled study 
of ataluren in nmDMD (Study 007), 57 patients received ataluren 10, 10, 20 mg/kg for 48 weeks.  
In addition, all patients in the ongoing open- label safety studies of ataluren in nmDMD  
(Studies 016 and 019) are receiving the 10, 10, 20 mg/kg dose level. As of 31 January 2015, the estimated median duration of exposure was 196.6 weeks for Study 016 (N=108) and 102.4 weeks for Study 019 (N=93).  Across the Phase 3, randomized, double -blinded, placebo- controlled 
study of ataluren in nmCF (Study 009) and its open- label extension (009e), a total of [ADDRESS_386729] received ataluren 10, 10, 20 mg/kg for ≥[ADDRESS_386730] 
received ataluren 10, 10, 20 mg/kg for ≥96 weeks. The controlled studies in nmDMD  (Study 
007) and nmCF (Study 009) have documented a favorable risk- benefit at the 10, 10, 20 mg/kg 
dose level in these indications [ Bushby 2014, Kerem 2014]. In nmDMD, ataluren has been 
conditionally approved at a dose of 10, 10, 20 mg/kg for the treatment of nmDMD. Based on the collective clin ical experience with ataluren 10, 10, 20 mg/kg, this dose level will be evaluated in 
patients with dystrophinopathy aged 2 to <5 years.  
Protocol Number PTC1240- GD-030-DMD  28 January 2016  
Version 2.0   
PTC Therapeutics, Inc. -  Confidential  
Page 53 of 63   
14.2.2.  Duration of  Therapy  
The primary objective of this Phase 2 study is to determine whether ataluren can be safe ly 
administered as a chronic treatment for patients 2 to <5 years of age. In patients ≥6 years old, 
ataluren has been generally well tolerated when administered chronically for >[ADDRESS_386731] experience that these tests can be perform ed with acceptable accuracy in this young patient population. 
 
[IP_ADDRESS].  Timed Function Tests  
Commonly employed over many years [ Brooke 1989, McDonald 1995] TFTs are relevant to the 
disease in that they assess functional aspects of proximal muscle strength required for everyday activities. TFTs are substantially abnormal in boys with DMD compared to healthy boys [Beenakker 2005b]. Worsening values have been correlated with time to wheelchair dependency 
and these tests can be sensitive to medical intervention [ Mendell 1989, Griggs 1991, Beenakker  
2005b]. Given their long- standing use, there is substantial experience with the conduct of the 
tests, the analyses of the data, and very high reproducibility has been demonstrated [ Mayhew  
2007].  
 
[IP_ADDRESS].  North Star Ambulatory Assessment  
The NSAA is a functional scale specifically designed for ambulant DMD patients.  The scale was developed and pi[INVESTIGATOR_314199] - and inter -observer reliability 
and has recently been used in a large multicenter study [ Mazzone 2011 ]. The scale includes 
items assessing abilities that are necessary to remain functionally ambulant, ie , ability to rise 
from the floor, ability to get from lying to sitting and sitting to standing, and that are known to progressively deteriorate in untreated patients. The scale also includes items assessing head raise and standing on heels that can be part ly present in the early stages of the disease and a number of 
activities such as hoppi[INVESTIGATOR_007], jumpi[INVESTIGATOR_007], and running [ Mazzone  2011].  
 
[IP_ADDRESS].  Ataluren Plasma  Concentrations  
Collection of blood for ataluren plasma concentration analysis is  critical for evaluating exposure - 
safety relationships in this population. Based on the preliminary popPK simulation results, 
sampling pre -dose and then at 1, 2, 4, 6, 8, and [ADDRESS_386732] -dose on Days 1 and 28 will provide 
information about single -dose a nd steady -state after 28 -day ataluren PK parameters in this 
population. Additionally, the ataluren PK profile has been well characterized in existing  
Phase 2a and Phase 3 studies in patients with CF. 
The high performance liquid chromatography with tandem m ass spectrometry (HPLC/MS -MS) 
method that will be used to quantify ataluren plasma concentrations has been fully validated in 
the context of the prior Phase 1 and Phase 2 studies. 
Protocol Number PTC1240- GD-030-DMD  28 January 2016  
Version 2.0   
PTC Therapeutics, Inc. -  Confidential  
Page 54 of 63   
14.2.4.  Safety  Monitoring  
In defining therapeutic activity in a particular  clinical setting, it is imperative that the drug’s 
safety profile be fully characterized. As is conventional in all clinical studies, proper description 
of each AE or laboratory abnormality requires an understanding of the type, incidence, timing, severit y, and relatedness to study drug. In this study, particular focus will be placed on 
monitoring for renal adverse findings. For consistency of interpretation, AEs will be coded using the standard MedDRA, and the severity of these events will be graded using the well -defined 
CTCAE Version 4.0. Standard definitions for seriousness will be applied. Particular attention will be paid to any AEs causing discontinuation of ataluren and to SAEs requiring rapid regulatory reporting.  
Protocol Number PTC1240- GD-030-DMD  28 January 2016  
Version 2.0   
PTC Therapeutics, Inc. -  Confidential  
Page 55 of 63   
15. BENEFITS AND  RISKS  
 
15.1. Benefits and Risks:  Non-Clinical  
Nonclinical safety pharmacology and toxicology studies indicate that ataluren has an acceptable 
safety profile. The findings seen pose a low human safety risk and the program supports chronic administration of ataluren for the treatment of nmCF in patients as young as 2 years of age.  
15.2. Benefits and Risks:  Clinical 
Multiple Phase [ADDRESS_386733] now shown the potential benefit and safety of ataluren 
in the treatment nmDMD in adults and children (details are provided i n the Ataluren IB).  
Decline in ambulation is the hallmark of dystrophinopathy, and the major goal of intervention 
during the ambulatory phase of dystrophinopathy is to maintain ambulation for as long as 
possible. Ataluren at a dose of 10, 10, 20 mg/kg slow ed the decline in ambulation in nmDMD 
patients. In the placebo- controlled study, Study 007, the targeted difference of 30 meters between 
ataluren 10, 10, 20 mg/kg and placebo in the [ADDRESS_386734] (6MWT) was achieved (Δ=31.3 
meters). The 30 -meter dista nce meets the threshold for minimal clinically important difference in 
dystrophinopathy and other diseases, and is in the range of the 6MWT results for approved therapi[INVESTIGATOR_14953] a variety of conditions. The 30- meter distance is meaningful to dystrophinopathy 
patients, providing greater ability to walk in their daily lives, for example, walking to and from the school bus and taking part in social activities.  
The time -to-event analysis of 6MWT progression further showed that ataluren 10, 10, 20 mg/kg 
slowed disea se progression in patients with nmDMD. Only 26% of patients who received 
ataluren 10, 10, 20 mg/kg, compared with 44% of the patients who received placebo, had persistent 10% worsening in the 6MWT at Week 48. Delaying ambulatory decline provides direct cli nical benefit by [CONTACT_314253] a longer period of self -sufficiency before 
transitioning to full -time wheelchair use. Maintenance of ambulatory capacity can prevent, delay 
the onset of, or reduce the severity of scoliosis, a debilitating complic ation of dystrophinopathy, 
and is beneficial to the patient’s pulmonary status.  
Positive trends in secondary endpoints in Study 007 support the 6MWT results. Patients who 
were treated with ataluren 10, 10, 20 mg/kg trended toward less decline in muscle function than 
patients who were treated with placebo and met the threshold (~1.5 seconds) for clinically 
meaningful differences. Among the TFTs, the largest effect for ataluren 10, 10, 20 mg/kg was seen in stair climbing, which is one of the most difficult ac tivities of daily living for patients with 
dystrophinopathy. Positive trends, favoring ataluren 10, 10, 20 mg/kg over placebo were also observed for TFT method grading, accidental fall frequency, activity and wheelchair use in the community setting, myometry, and patient -reported physical functioning domain of the Pediatric 
Quality of Life Inventory.  The consistency of these findings across outcome measures supports a treatment effect of ataluren 10, 10, 20 mg/kg in patients with nmDMD.  
 
15.3. Benefit/Risk  Concl usions  
Dystrophinopathy is a disabling and life -threatening genetic disorder resulting from mutations in 
the gene encoding the dystrophin gene. Dystrophin dysfunction leads to multiple organ 
Protocol Number PTC1240- GD-030-DMD  28 January 2016  
Version 2.0   
PTC Therapeutics, Inc. -  Confidential  
Page 56 of 63   
dysfunction starting in early childhood. An urgent unmet medical need exists for a therapy that 
addresses the underlying cause of nmDMD, a condition with high unmet medical need. Ataluren 10, 10, 20 mg/kg represents the first potentially disease -modifying therapy for a subset of 
patients with this s everely disabling, progressive, and ultimately fatal disease. 
The collective nonclinical and clinical data provide the basis for the continued development of ataluren treatment for nmDMD. The clinical efficacy data, in addition to an overall generally favorable safety profile collected from Phase 2 and 3 clinical trials supports a positive benefit - 
risk profile for ataluren. Appropriate safety monitoring and laboratory evaluation, as detailed in 
Section 14, is incorporated in this protocol in order to minimize risk to study participants. The 
current trial (Study 030) is feasible and will provide additional safety, PK, efficacy, and exposure data of ataluren in young children with nmDMD.  
Participants in this trial have the pote ntial for direct benefit from treatment with ataluren, which 
justifies the known and potential risks. Substantial nonclinical and clinical safety experience provides appropriate risk -benefit information that supports the conduct of this study. This 
informa tion is detailed in the Ataluren IB and is summarized in Section 9.8 of the IB. The 
potential risks (real and theoretical) have been weighed against the expected benefits for the children enrolled in the clinical trial. It is believed that the balance of r isks versus expected 
benefits will be positive for the clinical trial.  
Protocol Number PTC1240- GD-030-DMD  28 January 2016  
Version 2.0   
PTC Therapeutics, Inc. -  Confidential  
Page 57 of 63   
16. BIBLIOGRAPHY  
Amrani N, Ganesan R, Kervestin S, Mangus DA, Ghosh S, Jacobson A. A faux 3′ -UTR 
promotes aberrant termination and triggers nonsense -mediated mRNA decay. Nature 2004 
Nov;432:112. 
Barton -Davis ER, Cordier L, Shoturma DI, Leland SE, Sweeney HL. Aminoglycoside antibiotics 
restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest. 1999 Aug;104(4):375-
81. Beenakker EA, Fock JM, Van Tol MJ, Maurits NM, Koopman HM, Brouwer OF, Van der 
Hoeven JH. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Arch Neurol. 2005a Jan;62(1):128- 32. 
Beenakker EA, Maurits NM, Fock JM, Brouwer OF, van der Hoeven JH. Functional abilit y and 
muscle force in healthy children and ambulant Duchenne muscular dystrophy patients. Eur J Paediatr Neurol. 2005b;9(6):387- 93. Epub 2005 Aug 15. 
Biggar WD, Gingras M, Fehlings DL, Harris VA, Steele CA. Deflazacort treatment of Duchenne muscular dystrophy. J Pediatr. 2001 Jan;138(1):[ADDRESS_386735]. 2006 Apr;16(4):249- 55. 
Boland BJ, Silbert PL, Groover RV, Wollan PC, Silverstein MD. Skeletal, cardiac, and smooth muscle failure in Duchenne muscular dystrophy. Pediatr Neurol. 1996 Jan;14(1):7- 12. 
Brooke MH, Fenichel GM, Griggs RC, Mendell JR, Moxley R, Florence J, King WM, Pandya S , 
Robison J, Schierbecker J, et al. Duchenne muscular dystrophy: patterns of clinical progression 
and effects of supportive therapy. Neurology. 1989 Apr;39(4):475- 81. 
Bushby K, Finkel R, Wong B, Barohn R, Campbell C, Comi GP, Connolly AM, Day JW, Flanigan KM, Goemans N, Jones KJ, Mercuri E, Quinlivan R, Renfroe JB, Russman B, Ryan MM, Tulinius M, Voit T, Moore SA, Sweeney HL, Abresch RT, Coleman KL, Eagle M, Florence J, Gappmaier E, Glanzman AM, Henricson E, Barth J, Elfring GL, Reha A, Spi[INVESTIGATOR_314200], O'Donnel l MW, Peltz SW, McDonald CM; PTC124- GD-007-DMD Study Group. Ataluren 
treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve. [ADDRESS_386736];50(4):477- 87. 
Ciafaloni E, Fox DJ, Pandya S, Westfield CP, Puzhankara S, Romitti PA, Mathews KD, Mill er 
TM, Matthews DJ, Miller LA, Cunniff C, Druschel CM, Moxley RT. Delayed diagnosis in duchenne muscular dystrophy: data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet). J Pediatr. 2009 Sep;155(3):380- 5. 
Clancy JP, Beb ok Z, Ruiz F, King C, Jones J, Walker L, Greer H, Hong J, Wing L, Macaluso M, 
Lyrene R, Sorscher EJ, Bedwell DM. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am J Respir Crit Care Med. 2001 Jun;163(7):1683- 92. 
Protocol Number PTC1240- GD-030-DMD  28 January 2016  
Version 2.0   
PTC Therapeutics, Inc. -  Confidential  
Page 58 of 63   
Clancy JP, Konstan MW, Rowe SM, Accurso F, Zeitlin P, Moss R, Bebok Z, Northcutt V, 
Elfring G, Miller L, Hirawat S. A Phase 2 study of PTC124 in cystic fibrosis patients harboring 
premature stop mutations. Pediatr Pulmonol 2006;40 Suppl29:301 (abst #269). 
Dent KM, Dunn DM, von Niederhausern AC, Aoyagi AT, Kerr L, Bromberg MB, Hart KJ, 
Tuohy T, White S, den Dunnen JT, Weiss RB, Flanigan KM. Improved molecular diagnosis of dystrophinopathies in an unselected clinical cohort. A m J Med Genet A. 2005 Apr 
30;134(3):295- 8. 
Du M, Jones JR, Lanier J, Keeling KM, Lindsey JR, Tousson A, Bebok Z, Whitsett JA, Dey CR, Colledge WH, Evans MJ, Sorscher EJ, Bedwell DM. Aminoglycoside suppression of a premature stop mutation in a Cftr -/- mouse  carrying a human CFTR -G542X transgene. J Mol 
Med. 2002 Sep;80(9):595- 604. 
Du, M., X. Liu, et al. PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR -G542X nonsense allele in a CF mouse model. Proc Nat Acad Sci [LOCATION_003] 2008 
105(6): 2064- 9. 
Eagle M, Baudouin SV, Chandler C, Giddings DR, Bullock R, Bushby K. Survival in Duchenne muscular dystrophy: improvements in life expectancy since [ADDRESS_386737]. 2002 Dec;12(10):926 -9. 
Fenichel, G. M., J. M. Florence, et al. Long- term benefit from prednisone therapy in Duchenne 
muscular dystrophy. Neurology 1991a 41(12): 1874- 7. 
Fenichel, G. M., J. R. Mendell, et al. A comparison of daily and alternate -day prednisone therapy 
in the treatment of Duchenne muscular dystrophy. Arch Neurol 1991b. 48(6): 575- 579. 
Finkel RS, Flanigan KM, Wong B, Bönnemann C, Sampson J, Sweeney HL, Reha A, Northcutt 
VJ, Elfring G, Barth J, Peltz SW. Phase 2a study of ataluren -mediated dystrophin production in 
patients with nonsense mutation Duchenne muscular dystrophy. PLoS One. 2013 Dec 
11;8(12):e81302.  
Finsterer J, Stollberger C. The heart in human dystrophinopathies. Cardiology 2003 99(1):1- 19. 
Food and Drug Administration Center for Drugs Evaluation Research (2014). Draft Guidance for Industry: General Clinical Pharmacology Considerations for Pediatric Studies for Drugs and Biological Products (FDA Maryland).  
Goldmann, T., N. Overlack, et al. PTC124- mediated translational readthrough of a nonsense 
mutation causi ng Usher syndrome type 1C. Hum Gene Ther 2011.22(5): 537- 47. 
Griggs RC, Moxley RT 3rd, Mendell JR, Fenichel GM, Brooke MH, Pestronk A, Miller JP. Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. C linical Investigation of Duchenne Dystrophy Group. Arch Neurol. 1991 Apr; 
48(4): 383- 8. 
Gulati S, Saxena A, Kumar V, Kalra V. Duchenne muscular dystrophy: prevalence and patterns of cardiac involvement. Indian J Pediatr. 2005 May;72(5):389- 93. Comment in: Indian J Pediatr. 
2007 Feb;74(2):209; author reply 210-2. 
Hirawat S, Elfring GL, Leonard EM, Miller LL. Request for FDA orphan drug designation for ataluren as treatment of Duchenne muscular dystrophy. PTC Therapeutics Orphan Drug  
Protocol Number PTC1240- GD-030-DMD  [ADDRESS_386738] ication, 2004a Dec (designation granted 2005 Jan; ref 
http://www.fda.gov/orphan /designat/alldes.rtf; # 04 1972). 
Hirawat S, Elfring GL, Mathews J, Miller LL. Request for EMEA orphan product designation 
for atal uren as treatment of Duchenne muscular dystrophy. PTC Therapeutics Orphan Product 
Designation Application, 2004b Dec (designation granted 2005 May; ref http://pharmacos.eudra.org/F 2/register/alforphreg.htm;  # EU/3/05/278).  
Hirawat S, Welch EM, Elfring GL, Northcutt VJ, Paushkin S, Hwang S, Leonard EM, Almstead NG, Ju W, Peltz SW, Miller LL. Safety, tolerability, and pharmacokinetics of ataluren, a  
non-aminoglycoside, nonsense mutati on suppressor, following single - and multiple -dose 
administration to healthy male and female adult volunteers. J Clin Pharmacol 2007 Apr;47(4):430- 4. 
Kayali R, Ku JM, Khitrov G, Jung ME, Prikhodko O, Bertoni C. Read- through compound 13 
restores dystrophin expression and improves muscle function in the mdx mouse model for Duchenne muscular dystrophy. Hum Mol Genet. 2012 Sep;21(18):4007- 20. Epub 2012 Jun 12. 
Khurana TS, Davies KE. Pharmacological strategies for muscular dystrophy. Nat Rev Drug Discov. 2003 Ma y;2(5):379- 390. 
Kerem E, Hirawat S, Armoni S, Yaakov Y, Shoseyov D, Cohen M, Nissim -Rafinia M, Blau H, 
Rivlin J, Aviram M, Elfring GL, Northcutt VJ, Miller LL, Kerem B, Wilschanski M. Effectiveness of PTC124 treatment of cystic fibrosis caused by [CONTACT_314254]: a prospective phase II trial. Lancet. 2008 Aug; 372(9640):719- 27. 
Kerem E, Konstan MW, De Boeck K, Accurso FJ, Sermet -Gaudelus I, Wilschanski M, Elborn 
JS, Melotti P, Bronsveld I, Fajac I, Malfroot A, Rosenbluth DB, Walker PA, McColley SA, Knoop C, Quattrucci S, Rietschel E, Zeitlin PL, Barth J, Elfring GL, Welch EM, Branstrom A, 
Spi[INVESTIGATOR_314200], Peltz SW, Ajayi T, Rowe SM; Cystic Fibrosis Ataluren Study Group. Ataluren for the treatment of nonsense -mutation cystic fibrosis: a randomised, double -blind, placebo - 
controlled phase 3 trial. Lancet Respir Med. 2014 Jul;2(7):539- 47. 
Lapi[INVESTIGATOR_314201], Kakkar R, McNally EM. The dystrophin glycoprotein complex: signaling strength and integrity for the sarcolemma. Circ Res. 2004 Apr 30;94(8):1023- 31. 
Mayhew JE, Florence JM, Mayhew TP, Henricson EK, Leshner RT, McCarter RJ, Escolar DM. 
Reliable surrogate outcome measures in multicenter clinical trials of Duchenne muscular dystrophy. Muscle Nerve. 2007 Jan;35(1):36- 42. 
Mazzone E, Vasco G, Sormani MP, Torrente Y, Be rardinelli A, Messina S, D'Amico A, Doglio 
L, Politano L, Cavallaro F, Frosini S, Bello L, Bonfiglio S, Zucchini E, De Sanctis R, Scutifero M, Bianco F, Rossi F, Motta MC, Sacco A, Donati MA, Mongini T, Pi[INVESTIGATOR_9384] A, Battini R, Pegoraro E, Pane M, Gasperini S, P revitali S, Napolitano S, Martinelli D, Bruno C, Vita G, Comi G, 
Bertini E, Mercuri E. Functional changes in Duchenne muscular dystrophy: a 12- month 
longitudinal cohort study. Neurology. 2011 Jul 19;77(3):250- 6. 
McDonald  CM, Abresch  RT, Carter  GT, Fowler  WM Jr, Johnson ER, Kilmer  DD, Sigford  BJ. 
Profiles of neuromuscular diseases. Duchenne muscular dystrophy. Am J Phys Med Rehabil. [ADDRESS_386739];74([ADDRESS_386740]):S70- 92. 
McDonald CM. Physical activity, health impairments, and disability in neuromuscular di sease. 
Protocol Number PTC1240- GD-030-DMD  28 January 2016  
Version 2.0   
PTC Therapeutics, Inc. -  Confidential  
Page 60 of 63  Am J Phys Med Rehabil. 2002 Nov;81([ADDRESS_386741]):S108- 20. 
 
McDonald CM, Widman LM, Walsh DD, Walsh SA, Abresch RT. Use of step activity 
monitoring for continuous physical activity assessment in boys with Duchenne muscular 
dystrophy. Arch Phys Med Rehabi l. 2005a Apr;86(4):802- 8. 
McDonald CM, Widman L, Abresch RT, Walsh SA, Walsh DD. Utility of a step activity monitor for the measurement of daily ambulatory activity in children. Arch Phys Med Rehabil. 2005b Apr;86(4):793- 801. 
Mendell JR, Moxley RT, Griggs RC, Brooke MH, Fenichel GM, Miller JP, King W, Signore L, Pandya S, Florence J, et al. Randomized, double -blind six- month trial of prednisone in 
Duchenne's muscular dystrophy. N Engl J Med. 1989 Jun 15;320(24):1592- 7. 
Phillips MF, Quinlivan RC, Edwards RH, Calverley PM. Changes in spi[INVESTIGATOR_314202] a 
prognostic marker in patients with Duchenne muscular dystrophy. Am J Respir Crit Care Med. 2001 Dec 15;164(12):2191- 4. 
Politano L, Nigro G, Nigro V, Pi[INVESTIGATOR_314203] G, Papparella S, Paciello O, Comi LI. Gentamicin administration in Duchenne patients with premature stop codon. Preliminary results. Acta Myol. 2003 May;22(1):15- 21. 
Pradhan S, Ghosh D, Srivastava NK, Kumar A, Mittal B, Pandey CM, Singh U. Prednisolone in Duchenne muscular dystrophy with imminent loss of ambulation. J Neurol. [ADDRESS_386742];253(10):1309- 16. 
Sachs AB, Varani G. Eukaryotic translation initiation: there are (at least) two sides to every story. Nat Struct Biol. 2000 May;7(5):356- 61. 
Sermet -Gaudelus I, Boeck KD, [COMPANY_017] GJ, Vermeulen F, Leal T, Mogenet A, Roussel D, 
Fritsch J, Hanssens L, Hirawat S, Miller NL, Constantine S, Reha A, Ajayi T, Elfring GL, Miller 
LL. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense m utation cystic fibrosis. Am J Respir Crit Care 
Med. 2010 Nov 15;182(10):1262- 72. 
Simonds AK, Muntoni F, Heather S, Fielding S. Impact of nasal ventilation on survival in hypercapnic Duchenne muscular dystrophy. Thorax. 1998 Nov;53(11):949- 52. Comment in: 
Thorax. 1999 Jun;54(6):564. 
Tan, L., S. B. Narayan, et al. PTC124 improves readthrough and increases enzymatic activity of the CPT1A R160X nonsense mutation. J Inherit Metab Dis 2011. 34(2): 443- 7. 
Tangsrud S, Petersen IL, Lodrup Carlsen KC, Carlsen KH. Lung function in children with Duchenne's muscular dystrophy. Respir Med. 2001 Nov;95(11):898- 903. 
Wang, D., C. Shukla, et al.Characterization of an MPS I -H knock -in mouse that carries a 
nonsense mutation analogous to the human IDUA -W402X mutation. Mol Genet Metab 2010. 
99(1): 62- 71. 
Wang Y, Jadhav PR, Lala M, Gobburu J. Clarification on precision criteria to derive sample size when designing pediatric pharmacokinetic studies. J Clin Pharmacol. 2012;52:1601- 1606. 
Welch EM, Wong W, Peltz, SP. Translation termination: It’s not the end of the story. In Sonenberg N, Hershey JWB, and Matthews M, eds. Translational control of gene expression. 
Protocol Number PTC1240- GD-030-DMD  28 January 2016  
Version 2.0   
PTC Therapeutics, Inc. -  Confidential  
Page 61 of 63  2000 Cold Spring Harbor Press, [LOCATION_001]: 467- 485. 
 
Welch E M, Barton ER, et al. PTC124 targets genetic disorders caused by [CONTACT_314254]. 
Nature 2007. 447(7140): 87- 91. 
Wilschanski M, Yahav Y, Yaacov Y, Blau H, Bentur L, Rivlin J, Aviram M, Bdolah- Abram T, 
Bebok Z, Shushi L, Kerem B, Kerem E. Gentamicin- induced correction of CFTR function in 
patients with cystic fibrosis and  CFTR stop mutations. N Engl J Med. [ADDRESS_386743] 9;349(15):1433-
41. 
Wilschanski M, Miller LL, Shoseyov D, Blau H, Rivlin J, Aviram M, Cohen M, Armoni S, 
Yaakov Y, Pugatsch T, Cohen- Cymberknoh M, Miller NL, Reha A, Northcutt VJ, Hirawat S, 
Donnelly K, Elfring G L, Ajayi T, Kerem E. Chronic ataluren (PTC124) treatment of nonsense 
mutation cystic fibrosis. Eur Respir J. 2011 Jul;38(1):59- 69. 
Worton RG, Molnar MJ, Brais B and Karpati G. The muscular dystrophies. In: Scriver CR , Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular basis of inherited disease. 8th ed. Vol. 4. [LOCATION_001]: McGraw -Hill, 2001:5493- 523. 